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Zusammenfassung 
 
Das anaplastisch-großzellige Lymphom (ALCL) ist ein malignes T-Zell-Lymphom, das nach 
der WHO-Klassifikation zu den Non-Hodgkin-Lymphomen (NHL) gezählt wird. Es wurde 
erstmals 1985 als eigenständige Tumorentität beschrieben. ALCL tritt vor allem bei Kindern 
und Jugendlichen auf, aber auch ältere Erwachsene können betroffen sein. Etwa 15 % der 
kindlichen NHL gehen auf ALCL zurück. Bei 50-60% der ALCL Patienten ist eine 
chromosomale Translokation beobachtbar, die das Gen für die anaplastische 
Lymphomkinase (ALK) einschließt. Das dadurch entstehende onkogene Fusionprotein, 
Nucleophosmin anaplastischeLymphomkinase (NPM-ALK), bewirkt eine konstitutive 
Aktivierung der Rezeptor-Tyrosinkinasefunktion und nachgeschalteter Signalkaskaden wie 
z.B. von STAT3, PI-3K/Akt und mTOR.  
Bei der Therapie maligner Lymphome spielt die Chemotherapie, teilweise ergänzt durch die 
Strahlentherapie, eine entscheidende Rolle. Viele Zytostatika verursachen jedoch 
schwerwiegende Nebenwirkungen und sind selbst karzinogen. Daher erscheint eine 
zielgerichtete Therapie, die selektiv Signaltransduktionswege von Tumorzellen  inhibiert, als 
viel versprechende Alternative für die Therapie von malignen hämatologischen 
Erkrankungen sowie auch von  soliden Tumoren.  
Die Diagnose maligner Lymphome wird mittels histopathologischer Untersuchung nach 
Biopsie eines betroffenen Lymphknotens gestellt. Die Untersuchung des Ausbreitungsgrades 
eines malignen Tumors (Staging) vor Therapiebeginn sowie die Kontrolle der Effizienz einer 
angewandten Therapie werden nicht invasiv mittels bildgebender Verfahren durchgeführt. 
Dabei ist die Computertomographie (CT) das derzeit am häufigsten angewandte Verfahren 
bei malignen Lymphomen. Allerdings lassen sich mit CT nur vergleichsweise große Tumore 
nachweisen. Daneben liefert die CT keine Einblicke in den Stoffwechsel der Tumorzellen und  
Läsionen, die nur schwachen Kontrast zum umgebenden, gesunden Gewebe aufweisen, 
werden nicht erkannt. Mittels der [18F]-FDG Positronen-Emissions-Tomographie (PET) lässt 
sich die Effizienz einer Therapie beim malignen Lymphom verfolgen. Zusätzlich können mit 
[18F]-FDG-PET metabolische Veränderungen in malignen Lymphomen erkannt werden. Da 
jedoch auch Entzündungszellen mit erhöhtem Glukosebedarf [18F]-FDG anreichern, kommt 
es in der Tumordiagnose auch zu falsch positiven Befunden. Dagegen akkumuliert das 
Thymidin-Analogon [18F]-FLT (3'-Desoxy-3'-[18F] fluorothmidine) in Tumorgewebe aufgrund 
der stark erhöhten Proliferationsaktivität von Tumorzellen. [18F]-FLT-PET ermöglicht daher, 
im Gegensatz zur [18F]-FDG-PET, eine selektive Bildgebung der Tumorproliferation.  
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Das Ziel dieser Studie war es, die Anreicherung von [18F]-FLT als Surrogat-Marker zur 
Kontrolle des Therapieerfolgs, in einer frühen Phase nach Applikation einer zielgerichteten 
Therapie zu etablieren. Dazu wurden neun verschiedene ALK-positive ALCL-Zelllinien in 
vitro und zwei davon auch im Tiermodell untersucht. An den ALCL-Zelllinien wurde die 
zytotoxische Wirkung des HSP90-Inhibitors NVP-AUY922, des mTOR-Inhibitors RAD001 
(Everolimus), und des PI3K/Akt Inhibitors BGT226 analysiert. Diese Inhibitoren hemmen 
nachweislich ALK-abhängige Signaltransduktionswege. Ihre zytotoxische Wirkung wurde in 
vitro mittels MTT-Assay, Analyse des Zellzyklus-Arrests, [18F]-FDG und [18F]-FLT 
Aufnahme, sowie mittels Western-Blot Analyse von Proteinen der ALK-Signalwege 
untersucht. Weiterhin wurde die therapeutische Effizienz der Inhibitoren an immundefizienten 
SCID Mäusen mit ALK-positiven s.c. Xenotransplantaten (SUDHL-1, Karpas299) untersucht. 
Die Effizienz der Inhibitor-Therapie wurde mittels [18F]-FDG- und [18F-]FLT-PET überwacht.  
SUDHL-1-Zellen zeigten in vitro zytotoxische Reaktionen unterschiedlicher Stärke im 
Hinblick auf die drei eingesetzten Inhibitoren. Außerdem wurde eine signifikante Reduktion 
der [F18]-FLT Aufnahme in SCID Mäusen mit SUDHL-1 Xenotransplantaten bereits 5 Tage 
nach Beginn der zielgerichteten Therapie bei allen Inhibitoren beobachtet. Mittels 
Immunhistochemie konnte an Tumorschnitten eine Abnahme der Ki-67 Färbung und eine 
Zunahme der Färbung von cleaved Caspase-3 gezeigt werden, entsprechend einer 
Abnahme der Zellproliferations-Rate und einer Zunahme der Apoptose-Rate. Im Gegensatz 
dazu zeigte sich nur eine unwesentliche Verringerung in der Aufnahme von [F18]-FDG. In 
Karpas299 Xenotransplantaten, die sich als resistent gegen Behandlung mit NVP-AUY922, 
jedoch als empfindlich gegenüber RAD001 Behandlung erwiesen, waren eine Zunahme der 
[F18]-FLT Aufnahme am Tag 2 nach der Verabreichung von NVP-AUY299 sowie eine 
signifikante Reduktion der [F18]-FLT Aufnahme nach Applikation von RAD001 beobachtbar. 
Zusammenfassend belegen die Ergebnisse, dass mittels [F18]-FLT-PET, nicht aber mittels 
[F18]-FDG-PET, eine frühe Prognose hinsichtlich der Wirksamkeit der angewandten 
Inhibitor-Therapie getroffen werden kann. 
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Summary 
 
Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving 
aberrant T-cells. It features in the World Health Organisation (WHO) classification of 
lymphomas. The anaplastic large-cell lymphoma occurs mainly in children and young people, 
However, older adults can also be affected. It makes up about 15% of the child's non-Hogkin 
lymphomas. 50-60% of anaplastic large cell lymphoma (ALCL) are associated with the 
t(2;5)(p23;q53) chromosomal translocation involving the anaplastic lymphoma kinase (ALK) 
gene. ). A number of studies have shown that the constitutively active tyrosine kinase 
function of NPM-ALK is a key oncogenic event in the pathogenesis of t(2;5)-positive ALCLs, 
which leads to the constitutive activation of several signalling pathways including the STAT3, 
PI-3K/Akt and mTOR pathways . 
In the treatment of malignant lymphomas, chemotherapy , complemented by radiation 
therapy, plays a crucial role. But many cytotoxic drugs cause serious side effects and are 
even carcinogenic. Meanwhile, targeted therapy or molecularly targeted therapy is a type of 
medication that blocks the growth of cancer cells by interfering with specific targeted 
molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with 
all rapidly dividing cells (e.g. with traditional chemotherapy). Furthermore, targeted therapy 
has produced  promising results for various haematological malignancies and solid tumors. 
Therefore, targeted cancer therapies are expected to be more effective than current 
treatments and less harmful to normal cells. 
The diagnosis of malignant lymphomas requires a combination of morphological, molecular, 
genetic, immunohistochemical, and clinical data. Once the diagnosis HD or NHL has been 
established by biopsy of a particular site, determination of disease extent (staging) is 
important for therapeutic management and determining prognosis. Computed tomography 
(CT) is currently the most commonly used means for staging patients with malignant 
lymphoma. However, an important drawback of CT is its failure to detect pathologic changes 
in normal-sized structures and to detect lesions that have poor contrast with surrounding 
tissue. The increased glycolytic rate of malignant cells is the rationale behind the common 
use of 18F-fluoro-2-deoxyglucose (FDG) as a radiotracer in oncological PET studies. But 
because of the dependent on glucose metabolism is FDG not tumor specific, there is false-
positive result in inflammation and false-negative uptake in hyperglycaemic patients. The 
thymidine analog [18F]-FLT (3 -´deoxy-3 -´[18F]fluorothmidine) accumulates in tumor tissue 
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according to the proliferative activity, and [18F]-FLT PET therefore allows more specific 
imaging of tumor progresses. 
The purpose of this study is to establish FLT as superior surrogate marker for very early 
prediction of response to targeted drugs therapy in malignant lymphoma. We used various 
ALK-positive anaplastic large cell lymphoma (ALCL) cell lines to evaluate two inhibitors, the 
HSP90 inhibitor NVP-AUY922, and the mTOR inhibitor everolimus, both of which have 
shown to interfere with ALK-dependent oncogenic signal transduction. Their therapeutic 
effect was determined in vitro by MTT assay, [18F]fluorodeoxyglucose- (FDG) and 
[18F]fluorothymidine- (FLT) uptake, and by biochemical analysis of ALK-induced signalling. 
Micro FDG- and FLT-PET imaging studies in immunodeficient mice bearing ALCL 
xenotransplants were performed with the cell lines SUDHL-1 and Karpas299 to assess early 
treatment response to NVP-AUY922 or everolimus in vivo. SUDHL-1 cells showed sensitivity 
to both inhibitors in vitro. Importantly, we detected a significant reduction of FLT-uptake in 
SUDHL-1 bearing animals using both inhibitors compared to baseline as early as 5 days 
after initiation of targeted therapy. Immunostaining showed a decrease in Ki67 and an 
increase in cleaved caspase-3 staining. In contrast, FDG-uptake did not significantly 
decrease at early time points. Karpas299 xenotransplants, which are resistant to NVP-
AUY922 and sensitive to everolimus treatment, showed an increase of mean FLT-uptake on 
day 2 after administration of NVP-AUY299, but a significant reduction in FLT-uptake upon 
everolimus treatment. In conclusion, we show that FLT- but not FDG-PET is able to predict 
response to treatment with specific inhibitors very early in the course of treatment and thus 
enables early prediction of treatment efficacy. 
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1 Abbreviations 
 
7AAD: 7-Amino-Actinomycin  
ALCL: anaplastic large cell lymphoma  
ALK: anaplastic lymphoma kinase  
APS: Ammoniumpersulfat 
BFI: blood flow index 
BFU: 1-(2’-deoxy-2’-fluoro-beta-D-arabino-furanosy)-5-[76Br]-bromouracil  
BSA: bovine serum albumin 
BVD: in blood vessel density  
CT: Computed tomography  
DNA: Deoxyribonucleic acid 
DTT: dithiothreitol 
EDTA: ethylendiaminetetraacetic acid 
ELISA: Enzyme-linked immunosorbent assay 
ENT: equilibrative nucleoside transporters  
FACS: Fluorescence activated cell sorting  
FDG: 18F-fluoro-2-deoxyglucose 
FLT: 3 -´deoxy-3 -´[18F]fluorothmidine 
FMAU: 2’-[18F]-fluoro-beta-D-arabinofuranosyl-uracil  
FOXO: Forkhead box o class 
5-FU: 5-fluorouracil 
GI50: the concentration of the anti-cancer drug that inhibits the growth of cancer 
Hsp90: Heat shock protein 90 
HUVEC : human umbilical endothelial cell  
IC50: the concentration of a drug that inhibits a biological activity by 50% 
IHC: immunohistochemistry  
MCL: mantle cell lymphoma 
MK: midikine 
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mTOR: mammalian target of rapamycin 
mTORC1: mTOR Complex 1  
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NHL: non-Hodgkin lymphoma 
NPM-ALK: nucleophosmin-anaplastic lymphoma kinase 
P70 S6K: Ribosomal protein S6 kinase 
PBS: phosphate-buffered saline 
PCNA: proliferating cell antigen  
PD: pharmacodynamic 
PET: Positron emission tomography 
PI3K:  phosphatidylinositol 3-kinase  
PI: Propidium iodide 
PIP3: Phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3) 
PMSF: phenylmethylsulfonyl fluoride 
PTN: pleiotrophin 
PS: phosphatidylserine 
PVDF: polyvinylidene difluoride 
REAL: Revised European-American Lymphoma classification 
RNA: Ribonucleic acid 
ROI: regions of interest 
SCID: severe combined immunodeficient 
SDS: sodium dodecyl sulfate 
STAT3: Signal transducer and activator of transcription 3 
TBF: tumor blood flow 
TBR: Tumor-to-background ratios 
Temed: Tetramethylethylenediamine 
TK1:  thymidine kinase-1 
TSC: tuberous sclerosis 
VEGF: vascular endothelial growth factor   
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2 Introduction 
 
2.1 Hodgkin s´ and Non Hodgkin s´ lymphoma 
2.1.1 Classification of lymphoma 
Lymphoma is a cancer of the lymphocytes, a type of cell that forms part of the immune 
system. Typically, lymphoma is present as a solid tumor of lymphoid cells. Treatment might 
involve chemotherapy and in some cases radiotherapy and/or bone marrow transplantation, 
and can be curable depending on the histology, type, and stage of the disease (1). These 
malignant cells often originate in lymph nodes, presenting as an enlargement of the node (a 
tumor). It can also affect other organs in which case it is referred to as extra-nodal lymphoma. 
Extra-nodal sites include the skin, brain, bowels and bone. Lymphomas are closely related to 
lymphoid leukemias, which also originate in lymphocytes but typically involve only circulating 
blood and the bone marrow (where blood cells are generated in a process termed 
haematopoesis) and do not usually form static tumors (1). There are many types of 
lymphomas, and in turn, lymphomas are a part of the broad group of diseases called 
hematological neoplasms. 
Thomas Hodgkin published the first description of lymphoma in 1832, specifically of the form 
named after him, Hodgkin's lymphoma (2). Since then, many other forms of lymphoma have 
been described, grouped under several proposed classifications. The 1982 working 
formulation classification became very popular. It introduced the category non-Hodgkin 
lymphoma (NHL), divided into 16 different diseases. However, because these different 
lymphomas have little in common with each other, the NHL label is of limited usefulness for 
doctors or patients and is slowly being abandoned.  
The WHO Classification, published in 2001 and updated in 2008 (3), is the latest 
classification of lymphoma and is based upon the foundations laid within the "Revised 
European-American Lymphoma classification" (REAL). This system attempts to group 
lymphomas by cell type (i.e. the normal cell type that most resembles the tumor) and defining 
phenotypic, molecular or cytogenetic characteristics. There are three large groups: the B cell, 
T cell, and natural killer cell tumors. Other less common groups, are also recognized. 
Hodgkin lymphoma, although considered separately within the World Health Organization 
(and preceding) classifications, is now recognized as being a tumor of, albeit markedly 
abnormal, lymphocytes of mature B cell lineage.   
As reported from German Cancer Registry in 2008, the non-Hodgkin s´ lymphoma in male 
adults stood 10th (a total of 7270) in most frequently occurring type of cancer and 9th (a total 
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of 6430) in female adults. Hodgkin s´ lymphomas in adults are much rarer. In 2012, the 
Cancer Registry counts with 7800 new cases from male and 6500 new cases from female on 
NHL diagnosed. Additionally, it is reported from Cancer Registry of 1100 estimated new male 
cases and of 900 new female cases who developed Hodgkin s´ lymphoma.  
 
2.1.2 ALK-positive anaplastic large cell lymphoma 
ALK-positive anaplastic large cell lymphoma (ALCL) was recognized as a distinct entity in the 
2008 World Health Organization (WHO) classification of malignant lymphomas (4). 
Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving 
aberrant T-cells. The hallmark cells (and variants) show immunopositivity for CD30 (5)(also 
known as Ki-1). True positivity requires localisation of signal to the cell membrane and/or 
paranuclear region (cytoplasmic positivity is considered non-specific and non-informative). 
Another useful marker which helps to differentiate this lesion from Hodgkin lymphoma is 
Clusterin. The neoplastic cells have a golgi staining pattern (hence paranuclear staining), 
which is characteristic of this lymphoma. The cells are also typically positive for a subset of 
markers of T-cell lineage. However, as with other T-cell lymphomas, they are usually 
negative for the pan T-cell marker CD3. Occasional examples are of null (neither T nor B) 
cell type. These lymphomas show immunopositivity for ALK protein in 70% of cases. They 
are also typically positive for EMA. In contrast to many B-cell anaplastic CD30 positive 
lymphomas, they are negative for markers of Epstein-Barr Virus (EBV). 
50-60% of anaplastic large cell lymphoma (ALCL) are associated with the t(2;5)(p23;q53) 
chromosomal translocation involving the anaplastic lymphoma kinase (ALK) gene (6, 7). The 
t(2;5) results in the expression of the oncogenic fusion protein nucleophosmin-anaplastic 
lymphoma kinase (NPM-ALK). A number of studies have shown that the constitutively active 
tyrosine kinase function of NPM-ALK is a key oncogenic event in the pathogenesis of t(2;5)-
positive ALCLs, which leads to the constitutive activation of several signalling pathways 
including the STAT3, PI-3K/Akt and mTOR pathways  (8, 9). 
Other karyotype aberrations including oncogenic fusion of ALK to other fusion partners have 
been identified in inflammatory myofibroblastic tumors, non-small-cell lung cancersand other 
solid tumors (10, 11). Fusion proteins resulted from oncogenic translocations carry 
constitutive tyrosine kinase activity because of dimerization and kinas domain autoactivation 
induced by fusion partner. Although the exact function of full-length ALK is not fully 
understood, it is believed that it is involved in neuronal cell differentiation, 
regeneration,synapse formation and muscle cell migration (12). 
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In its native, full-length single chain receptor form, ALK consists of 1620 amino acids. Within 
these 1620 amino acids, there is a 1030 residue extracellular region. It contains multiple 
subdomains such as an LDL-A domain, a MAM domain (meprin, A5, mu), and a glycine-rich 
region (Fig. 1)(13, 14)and a cytoplasmic portion. It contains 563 residues coding for the 
kinase catalytic domain. This full-length form is implicated in malignancies where ALK 
promotes tumorigenesis via the activation by pleiotrophin (PTN) and midikine (MK) (15, 16). 
Upon the ligand binding, it leads to receptor dimerization and activation via trans-
autophosphorylation of tyrosine residues within kinase domain activation loop (A-loop) 
segments. Phosphorylation of sites outside the A-loop serve as docking sites for downstream 
SH2 and PTB domain-containing effector and adapter proteins involved in the signal 
transduction cascade. Genetic abnormalities or disease states leading to ALK 
hyperactivation manifest in oncogenic transformation from overstimulation of downstream 
STAT, Ras/Raf/MEK, PI3K/AKT, and PI3K/PLC- γ pathways involved in cell survival, 
differentiation and apoptosis (11). One of STAT signalling pathway is the STAT3 pathway 
(17-19).STAT3 has been proved to be oncogenic in a variety of human cancer (20-24). Many 
studies suggest that STAT3 activation is crucial for the pathogenesis of ALK-ALCL as well as 
NPM-ALK (17, 19, 25). Recently, the ALK locus was found to be a site of genetic alteration in 
the form of comatic and germline mutations that play a major role in advances 
neurovblastoma (26-28).  
 
Fig. 1: Full-length single chain receptor form of ALK ( according to Christian C. Lee et al. BJ 
2010) 
 
Moreover, recent studies suggest that ALK exhibits a unique peptide substrate specificity and 
autoactivation mechanism (29). In contrast to other RTKs, a narrower substrate peptide 
specificity profile is reported for ALK. Phosphorylating peptide substrates of ALK has greater 
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efficiency in corresponding to its own A-loop sequence than generic and conventional 
peptide substrates, frequently used in tyrosine kinase activity measurements (29).  
 
 
 
Fig. 2: The Anaplastic lymphoma kinase (ALK) signaling cascade (according to Yael P. et al. 
Clin Cancer Res 2009) 
 
Additionally, variant translocations involving ALK and other partner genes on chromosomes 1, 
2, 3, 17, 19 and 22 have been reported (12). These translocation result in abnormal 
expression of ALK chimeric proteins with tyrosine kinase activity and oncogenic properties 
(12). ALK fusion proteins can be detected using anti-ALK antibodies, which has crucial 
diagnostic value. (30, 31).The NPM-ALK kinase exhibits phosphotransferase activity (Fig. 2). 
Meanwhile, through its interaction with various ALK-adapter proteins, it induces cell 
transformation and increase cell proliferation in vitro. The chaperones heat shock proteins 90 
(Hsp90) and 70(Hsp70) play a critical role in the folding and maturation of several oncogenic 
protein kinases. This is because of perturbation of Hsp90 structure affects the stability and 
degradation of Hsp90- and Hsp70-bound substrates. This process is triggered by 
benzoquinone ansamycin antibiotics, a Hsp90-binding small molecule. 
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2.2 New therapeutic approaches for lymphoma and monitoring of the 
therapeutic response  
 
Targeted therapy against an oncogenic molecule or pathway has produced  promising 
results for various haematological malignancies and solid tumors such as chronic 
myelogenous leukemia (imatinib) (32) and lung cancer (gefitinib). Hsp90 is essential for 
eukaryotic cell survival. In many tumors, Hsp90 is either overexpressed and/or exclusively in 
an activated state with a high chaperoning efficiency (33). Hsp90 is an attractive cancer 
target, due to its frequent dysregulation in client proteins among solid and haematological 
malignancies. These client proteins include transcription factors (i.e. hormone receptors), 
signalling kinases (for example BCR-ABL, NPM-ALK) and chromatin remodelling factors. 
Hsp90 inhibitors affect multiple targets in signal transduction pathways by inactivating a large 
number of oncoproteins. This theory is supported by pre-clinical studies, where HSP90 
inhibitors induced cell cycle arrest and apoptosis in a variety of haematological and solid 
malignancies including lymphomas and sarcomas. 
Hsp90 inhibitors act synergistically with a range of standard therapeutic agents. This means 
Hsp90 inhibitors could be particularly effective in combination therapies. 
Hence, Hsp90 has attracted considerable interest in recent years as a potential therapeutic 
target for lymphoma and other malignancies (34). 
The phosphatidylinositol 3-kinase (PI3K/AKT) pathway is the pathway that is altered in many 
tumors as well as lymphomas (35). This multifunctional pathway has been recognized as a 
particularly attractive target for patients with lymphoma. “The PI3K pathway appears 
continuously deregulated among lymphoma malignancies,” reported Sonali M. Smith, MD, 
director of the Lymphoma Program at the University of Chicago Medical Center, Illinois. 
Molecular ties linked to abnormal PI3K pathway signaling have been demonstrated in mantle 
cell lymphoma (MCL) (36), non-Hodgkin lymphoma (37), as well as in Hodgkin lymphoma 
(38). Specifically, mTOR, a serine/threonine kinase that is a key downstream target of the 
PI3K pathway, as well as an important regulator of normal development, has been 
associated with lymphoma genesis.   
The PI3K/AKT pathway affects various aspects of malignant behaviors such as cell growth 
proliferation and survival signals (39, 40). Hsp90 inhibitors affect AKT activity indirectly 
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through depletion of upstream signalling molecules (for example, ERBB family members) 
and directly through preventing Hsp90-dependent conformational stability of AKT (41-43). 
Hsp90 is a ubiquitously expressed molecular chaperone playing an important role in the 
post-translational conformational maturation and in the activation of a large number of client 
proteins that have been implicated in oncogenesis (44). Hsp90 functions as a dimmer and 
operates in a highly regulated ATP-cycle together with a group of co-chaperones (45). 
Inhibition of the ATPase activity at the N-terminus of Hsp90 is used by clinical inhibitors. 
Currently, the most advanced HSP90 inhibitor in clinical trials are the benzoquinone 
ansamycin class. They have shown promising results in human tumor xenograft models (44, 
46)and are tested in phase II/III clinical trials for solid tumors and haematological 
malignancies. The most studied compound of this classis, tanespimycin or benzoquinone 
ansamycin antibiotics (17-AAG). It relatively poor physiochemical properties, poses a 
delivery challenge in clinical use (47). This issue is partially resolved from the development of 
the water-soluble analog alvespimycin (17-DMAG) (46). The 17-AGG hydroquinone IPI-504 
has also been developed as less toxic and/or more soluble drugs (48, 49). The development 
of Hsp90 inhibitors with more favourable pharmaceutical properties is being intensely 
investigated. NVP-AUY922 is a potential synthetic small-molecule Hsp90 inhibitor (50). NVP-
AUY922 is an isoxazole-base compound which competitively inhibits the ATPase activity of 
Hsp90. Heat shock proteins act as molecular chaperones. They are involved in the folding of 
cellular proteins. Many of heat shock proteins are also involved in the regulation of cell 
proliferation, survival, and apoptosis. Inhibition of Hsp90 by NVP-AUY922 shows degradation 
of client proteins. This translates into an anti-tumor effect of NVP-AUY922, which is shown in 
non-clinical in vitro and in vivo studies. Binding of NVP-AUY922 also induces a stress 
response that is manifested by changes to the Hsp90-p23 complex and increased levels of 
Hsp70. NVP-AUY922 is an ATP-competitive inhibitor of Hsp90. It prevents the binding of 
ATP to Hsp90 and impairs the formation a complex of Hsp90 with the co-chaperone p23, an 
essential for the function of Hsp90. NVP-AUY922 reduced the cellular levels of important 
client proteins in tumor cells, such as, ErbB2 (Her2) and p-AKT, indicating that inhibition of 
Hsp90 by NVP-AUY922 leads to destabilization and degradation of these proteins. In 
addition, NVP-AUY922 induces degradation of client proteins and inhibition of downstream 
signalling. At the cellular level, NVP-AUY922 leads to cell cycle arrest and apoptosis. This 
mediates inhibition of cell proliferation of a panel of tumor and non-tumor cell lines at low 
nanomolar concentrations. In vivo anti-tumor effect has been observed in a number of mouse 
xenograft models with corresponding effects on pharmacodynamic markers.  
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BGT266 is a potent pan-class I PI3K and mTOR inhibitor, belongs to the class of 
imidazoquinoline derivatives. The inhibitory effect of BGT226 is mediated through binding to 
Valine-882 and Serine-805 in the hinge region of the ATP-binding pocket of the p110 subunit 
of PI3K, displaying a flight preference for the α-isoform. Based on preclinical research from 
Novaris BGT266 effectively inhibits proliferation and colony formation of a variety of tumor 
cell lines. It also inhibits growth of tumors in a variety of mouse xenograft models, such as 
breast cancer, prostate cancer, glioblastoma multiforme, lung cancer and colorectal cancer 
models. BGT266 has no relevant inhibitory activity against either receptor tyrosine kinases 
involved in proliferation and survival (e.g. EGFR/HER-1, IGF-1R, cMet) or the angiogenic 
switch (e.g. Kdr, Tek, EpB4). However, it has inhibitory activity against AGC family kinase 
members known to be activated by the PI3K pathway (e.g. PDK1) and AKT/PKB itself. 
BGT226 dramatically reduces the phosphorylation of PKB, a direct downstream effector of 
PI3K. This biological activity correlates with strong inhibition of other effectors of PI3K 
signalling, such as p70 S6K protein and inhibition of proliferation and colony formation of a 
variety of tumor cell lines, regardless of their genetic background. Therefore, BGT226 was 
chosen as a PI3K inhibitor in our study to treat the ALCL ALK+ lymphoma. 
 
As a widely used small molecular inhibitor, RAD001 (everolimus) was also chosen to build up 
this research. RAD001 is a derivative of rapamycin. It acts as a signal transduction inhibitor. 
Its target is mTOR, a key serine-threonine kinase regulation protein synthesis and ultimately 
cell growth, cell proliferation, angiogenesis and survival. Downstream of PI3/AKT, mTOR can 
be considered as a component in the PI3K/AKT/mTOR pathway which is known to be 
dysregulated in numerous human cancers. Molecular epidemiological studies show that in 
addition to a high frequency in specific cancers, activation of the PI3K/AKT/mTOR pathway is 
often a characteristic of worsening prognosis (through increased aggressiveness), resistance 
to treatment, extension and progression.  
A variety of preclinical studies have confirmed the role of this pathway in tumor development. 
Moreover, function models have demonstrated that constitutive activation of kinases such as 
AKT, can lead to the inexorable development of cancers resembling those are characterized 
by frequent activation of the same kinase. This is complemented by demonstration of the 
antitumor activity of kinase inhibitors acting in vitro and in vivo. Many experiments (51-53) 
showed that RAD001 is capable of inhibiting the proliferation and growth of a wide spectrum 
of tumor cell lines and tumors. The antiproliferative effects of RAD001 are achieved in 
nanomolar concentrations that already show positive results in clinical trials. An important 
aspect of the antitumor effect of RAD001 is its potential to act on both tumor cells directly (to 
inhibit growth) and indirectly (by inhibiting angiogenesis). During observation of in vivo 
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sensitivity of xenograft, however, in vitro cells are detected to be resistance to RAd001. This 
means the drug has the potential to act on the vascular component of the supporting 
peritumoral stroma. The antiangiogenic property of RAD001 has been confirmed through 
experiments which demonstrate the effect of RAD001 in countering VEGF-induced 
proliferation of human umbilical endothelial cells (HUVECs) (54) in vitro. RAD001 has been 
in clinical development since 1996 to prevent rejection in patients undergoing solid organ 
transplants. It is developed by an immunosuppressant, associated with cyclosporine and 
glucocorticoids. In this context mTOR inhibition oppose interleukin-stimulated proliferation of 
activated T-lymphocytes. An antiproliferative effect on immuno-competent cells is another 
reason for investigation on the drug s´ activity in autoimmune diseases. The use of RAD001 
in the inhibition of intimal proliferation has been investigated after coronary angioplasty 
through its incorporation into drug-eluding stents.   
 
2.3 Lymphoma diagnosis and Imaging – CT and PET 
The diagnosis of malignant lymphomas requires a combination of morphological, molecular, 
genetic, immunohistochemical, and clinical data. Once the diagnosis HD or NHL has been 
established by biopsy of a particular site, determination of disease extent (staging) is 
important for therapeutic management and determining prognosis. Moreover, knowing the 
sites of involvement at time of diagnosis makes it possible to accurately restage at the end of 
therapy and document a complete remission (55, 56). Staging of HD and NHL is based on 
the Ann Arbor classification with the addition of a definition of bulky disease often referred to 
as the Cotswold modification (Table 1) (57). This staging system encompasses the number 
of sites of disease involved, the type of involvement (nodal or extra-nodal), and the 
distribution of disease (58). Computed tomography (CT) is currently the most commonly 
used means for staging patients with malignant lymphoma (55, 56). The introduction of CT in 
the early 1970s was a tremendous breakthrough in non-invasive imaging, and its potential for 
staging malignant lymphoma was soon recognized and investigated (59). Lymph nodes of 5 
mm or less in diameter can be detected throughout the whole body. In combination with 
powered injectors for rapid bolus administration of intravenous contrast medium, focal extra-
nodal lesions on the order of a few millimetres can be identified (60, 61).  
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Table 1. Cotswold and Ann-Arbor classification (Thomas C. Kwee et al. Blood 2008) 
 
Stage Involvement 
I Single lymph node region (I) or one extralymphatic site (IE) 
II Two or more lymph node regions, same side of the diaphragm (II) or 
local extralymphatic extension plus one or more lymph node regions 
same side of the diaphragm (IIE) 
III Lymph node regions on both sides of the diaphragm (III), which may be 
accompanied by local extralymphatic extension (IIIE) 
IV Diffuse involvement of one or more extralymphatic organs or sites 
Suffix 
A no systemic symptoms 
B presence of at least one of these symptoms: unexplained weight loss of 10% or 
more of body weight in the 
6 months preceding staging; recurrent unexplained fever > 38ºC; recurrent 
night sweats. 
Bulky 
tumor 
either a single mass exceeding 10 cm in the largest diameter or a mediastinal 
mass exceeding one third of the maximum transverse trans-thoracic diameter 
measured on a standard posterior-anterior chest X-ray at the level of the T5-T6 
intervertebral disk 
 
 
Determination of nodal involvement is based on size criteria. Lymph nodes with a short-axis 
diameter greater than 10 mm are generally considered positive. Furthermore, clustering of 
normal sized but prominent lymph nodes in the anterior mediastinum and the mesentery is 
suspicious for disease. The use of intravenous contrast medium is not helpful in 
differentiating normal from malignant lymph nodes. General criteria for extra-nodal 
involvement are organomegaly, abnormal mass or structural changes in a normal-sized 
organ, and abnormal contrast enhancement (61). 
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However, as Kwee et al. have described in 2008, an important drawback of CT is its failure to 
detect pathologic changes in normal-sized structures and to detect lesions that have poor 
contrast with surrounding tissue. Another weakness of CT is that it is not reliable in the 
detection of bone marrow disease, which, if present, by definition indicates stage IV disease 
(61). Furthermore, CT may not be able to differentiate residual viable tumor tissue from 
therapy-induced fibrosis. Additionally, two other CT studies reported a low-to-mode rate 
specificity in restaging malignant lymphoma (62, 63). 
Positron emission tomography (PET) was developed in the early 1970s soon after CT (64). 
PET is based on the use of positron-emitting radiopharmaceuticals and the detection in 
coincidence of the 2 nearly collinear 511-keV photons emitted following positron annihilation 
with an electron. The increased glycolytic rate of malignant cells is the rationale behind the 
common use of 18F-fluoro-2-deoxyglucose (FDG) as a radiotracer in oncological PET 
studies (65). Imaging of malignant lymphoma with FDG was first described in 1987 (66), and 
the first reports on FDG-PET as a whole-body staging method in malignant lymphoma 
appeared in the 1990s (67-70). PET technology has improved dramatically since its 
development. Initial patient imaging units had a system resolution greater than 15 mm, 
whereas current units have a 4 to 5 mm resolution (65). FDG-PET examinations for staging 
malignant lymphoma should be performed on dedicated (full ring) PET scanners, because 
dual-head gamma cameras in coincidence mode are unreliable in detecting lesions less than 
15 to 20mmin diameter (71-73).  
Functional imaging with positron emission tomography (PET) and the glucose analog [18F]-
FDG has been recently suggested to identify responding lymphomas and determine ongoing 
treatment in patients with malignant lymphoma (74, 75). This strategy is based on the 
assumption that viable cancer cells have a significantly higher glucose use compared to 
surrounding normal tissues. 
Therefore, the main advantage of FDG-PET over anatomical imaging techniques, such as 
CT, is its ability to detect metabolic changes in areas involved with malignant lymphoma 
before structural changes become visible. It also is likely that FDG-PET surpasses CT in 
differentiating residual viable tumor tissue from therapy-induced fibrosis (57). Indeed, 
accuracy of FDG-PET in restaging of malignant lymphoma seems to be higher than that of 
CT (57). Routinely, FDG avid malignant lymphomas (HD, diffuse large B-cell lymphoma, 
follicular lymphoma, and mantle cell lymphoma) are well visualized, both in initial staging and 
restaging (76-78). However, some subtypes of NHL, predominantly low-grade lymphomas, 
may have low or even no uptake of FDG. Nodal and extra-nodal marginal zone lymphomas 
(77-84), small lymphocytic lymphomas (85), primary duodenal follicular lymphoma (86), 
cutaneous T-cell lymphomas (87), and peripheral T-cell lymphomas (77) all have been 
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reported to be possibly FDG negative. Most recent advances in cancer treatment have 
derived from the development of disease-specific molecular-targeted agents. Deregulated 
cell cycle progression is a hallmark of various human cancers including malignant 
lymphomas. Notably, with respect to in vivo imaging, proliferative activity has been shown to 
be more specific for malignant tumors than that of glucose metabolism (88). The thymidine 
analog [18F]-FLT (3 -´deoxy-3 -´[18F]fluorothmidine) accumulates in tumor tissue according to 
the proliferative activity and that FLT-PET enables non-invasive imaging of tumor 
proliferation. FLT is accumulated after its phosphorylation by cellular thymidine kinase-1 
(TK1). TK1 is a key enzyme of the pyrimidine salvage pathway of DNA synthesis whose 
activity is higher in malignant than in benign cells (89, 90). Since this enzyme is only 
functional during the S-phase, uptake of FLT is tied to the cell proliferation (91). This has 
been substantiated by the correlations between FLT-uptake and TK enzyme activity and cell 
proliferation which is measured by Ki-67 and proliferating cell antigen (PCNA) expression 
(92-97). The reason to use [18F]-FLT as a surrogate marker for cellular proliferation is based 
on its substrate specificity for the cell cycle regulated protein TK1. Barthel et al. recently 
reported that in vivo uptake of [18F]-FLT is closely related to TK1 activity and cellular 
concentration of ATP (98).  Since, [18F]-FLT acts as chain terminator and only a small 
amount of intracellular [18F]-FLT is incorporated into DNA. [18F]-FLT is therefore not a direct 
marker of proliferation. However, several studies in humans show still a significant correlation 
of tumor proliferation and [18F]-FLT-uptake in lymphoma and other solid tumors (93, 99, 100). 
As a preclinical model for monitoring therapeutic response, a significant decrease of FLT-
uptake was observed in tumor-bearing mice as early as 24 hours after chemotherapy (101-
103). Importantly, in a clinical study, we were able to demonstrate that the reduction of FLT-
uptake in aggressive lymphomas after the first course of therapy correlates with response at 
the end of the treatment (104). 
Therefore, the [18F]-FLT as a proliferation marker as well as the golden standard [18F]-FDG 
are chosen to predict the therapeutic response in our study using anaplastic lymphoma 
kinase (ALK) -positive anaplastic large cell lymphoma (ALCL).   
 
2.4 Purpose 
The aim of this study is to establish FLT as an adequate and robust surrogate marker for 
response to treatment which can be used very early in the course a targeted drug therapy. 
Additionally, thymidine uptake in SCID mice bearing SUDHL-1 or Karpas299 lymphoma 
xenotransplants was assessed prior to and early in the course of therapy with Hsp90 inhibitor 
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NVP-AUY922, mTOR inhibitor RAD001 or PI3K inhibitor BGT266 using a modern micro 
PET-CT scanner. Tumor-to-background ratios (TBR) of the FLT-uptake were compared to 
those of corresponding FDG-PET scans. PET findings were correlated with histopathology 
and in-vitro data including cellular tracer uptake, cell cycle related protein expression, cell 
cycle distribution and viability assessment.  
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3 Methods 
 
3.1 Kinase inhibitors 
NVP-AUY922 (HSP 90 inhibitor), BGT226 (PI3K inhibitor) and RAD001 (mTOR inhibitor) 
were produced from Novartis (Consumer health GmbH, Germany). NVP-AUY922 and 
RAD001 were solubilised in 5% glucose solution to 200μM and 1μM, BGT266 was diluted 
with 0.01% HCl to 1μM as primer solution for cell treatment It was stored at -20°C and 
protected from light. The primer solution was then diluted in the concentration rang 0-1000 
nM for AUY922, 0-100 nM for BGT226 and 0-100 nM for RAD001 with DMEM for in vitro 
research. 
 
3.2 Cell culture 
The murine pro-B-lymphoid cell line Ba/F3 ((ALK)-positive ALCL cell, pro-B-cell, murine, 
COPE), was maintained in DMEM (Dulbecco's Modified Eagle Medium) (Invitrogen GmbH, 
Darmstadt Germany) and was recombinant with 10% fetal bovine serum, 1mM L-glutamine, 
1% penicilline/streptomycine (Invitrogen, Darmstadt Germany) and 1ng/ml murine 
recombinant interlerkin-3 (IL-3, R&D Systems, DPC Bierman GmbH, Wiesbaden, Germany). 
Ba/F3-NPM-ALK transformed cells and ALK+ALCL (JB-6: (ALK)-positive ALCL cell, human 
histiocytic lymphoma cell, ATCC; Karpas299: (ALK)-positive  ALCL cell, humen T cell 
lymphoma, ATCC; SUDHL-1: (ALK)-positive  ALCL cell, human histiocytic lymphoma cell, 
ATCC; SUP-M2: (ALK)-positive ALCL cell, human histiocytic lymphoma cell,ATCC; SR-789: 
(ALK)-positive ALCL cell, human histiocytic lymphoma cell, ATCC) were cultured in DMEM 
medium supplemented with 10% fetal bovine serum, 1mM L-glutamine, and 1% 
penicilline/streptomycine. All cell lines were cultured in an incubator (UniTec GmbH, 
Regensburg, Germany) at 37°C with 5% CO2.  
 
3.3 Cell counting 
For cell counting, 20μl cells with cell culture was mixed with trypan blue to 80μl Eppendorf 
Tubes Pipette (1:5 dilution), 20μl from the mixture was placed in Neubauer counting chamber, 
Under microscope, cells were counted in 4x16 large squares and thus the number of vital 
and dead (blue stained) cells determined. 
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3.4 Cell proliferation and viability assay 
Cells were seeded in 96-well flat-bottom plates and incubated with the indicated cytostatic 
drugs for 24h, 48h or 72h to determine of IC50. NVP-AUY922 stock solution was diluted in 
cell culture medium and tested in concentration ranging from 0 to 1000 nM. RAD001 and 
BGT266 were diluted from o to 100 nM. Cell density was adjusted to 5×105 or 2×105 cell/well 
for cell lines in final volume of 100 μl per well Cell viability and growth retardation was 
determined by the 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, which is a 
yellow tetrazolium (MTT) cell proliferation assay (Aqueous Celltiter96®, Promega, Mannheim, 
Germany). All experiments with cell lines were performed in threefold approach. Mean and 
standard deviation were determined to analyse the effect. 
 
3.5 Cell cycle distribution and apoptosis analysis (fluorescence activated 
cell sorting – FACS) 
Cell cycle distribution was detected using PI-staining. Propidium iodide (PI) binds to DNA by 
intercalating between the bases with little or no sequence preference and with a 
stoichiometry of one dye per 4.5 base pairs of DNA. PI also binds to RNA which treatment 
with nucleases to distinguish between RNA and DNA staining. When bind to nucleic acids, 
the absorption maximum for PI is 535 nm and the fluorescence emission maximum is 617 
nm. PI can be excited with a xenon or mercury-arc lamp or with the 488 line of an argon-ion 
laser. It is membrane impermeable and generally excluded from viable cells. PI is commonly 
used for identifying dead cells in a population and as a counterstain in multicolor fluorescent 
techniques. 
The 2×106 cells were collected after 24, 48 and 72 hours (For co-incubations with sequential 
exposure, treatment was started with 24 hours incubation for the first feed and the second 
feed was added to the first feed last 24hours of incubation, resulting in a total incubation time 
of 72hours.) of treatment and washed twice in phosphate-buffered saline, then fixed 
overnight using 70% ethanol. Following centrifugation the supernatant was discarded and the 
cell pellet was resuspended in 0.2% propidium iodide (Fluka, Heidelberg, Germany) dilution 
buffer and then supplemented with 80 μg/ml RNase (RNase, DNase free; Roche Diagnostics 
GmbH, Mannheim, Germany). Samples were kept at 37°C for 30 min and then were 
analysed by flow cytometry (FACS Calibur System; BD Biosciences, Heidelberg, Germany). 
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Fragments of damaged or apoptotic cells were determined as pre-G1 fraction using Flow 
Cytometry Analysis software (FlowJo). All experiments were performed in triplicate. 
Apoptosis is a process, occurs during embryonic development as well as in maintenance of 
tissue homeostasis. The apoptotic program is characterized by several morphologic features, 
such as loss of plasma membrane asymmetry and attachment, condensation of the 
cytoplasm or nucleus, as well as internucleosomal cleavage of DNA. Loss of plasma 
membrane is one of the earliest features. In apoptotic cells, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the plasma 
membrane, thereby exposing PS to the external cellular environment. Annexin V is a 35-36 
kDa Ca2+ dependent phospholipid-binding protein which has a high affinity for PS, and binds 
to cells with exposed PS. Annexin V could be conjugated to fluorochromes including FITC. 
This format retains its high affinity for PS and thus serves as a sensitive probe for flow 
cytometric analysis of cells that are undergoing apoptosis. Since externalization of PS occurs 
in the earlier stages of apoptosis, FITC Annexin V staining can identify apoptosis at an earlier 
stage than assays based on nuclear changes such as DNA fragmentation. FITC Annexin V 
staining precedes the loss of membrane integrity which accompanies the latest stages of cell 
death resulting from either apoptotic or necrotic processes. Therefore, staining with FITC 
Annexin V is typically used in conjunction with a vital dye such as propidium iodide (PI) or 7-
Amino-Actinomycin (7-AAD) to allow the investigator to identify early apoptotic cells (PI 
negative, FITC Annexin V positive). Viable cells with intact membranes exclude PI, whereas 
the membranes of dead and damaged cells are permeable to PI. For example, cells that are 
considered viable are FITC Annexin V and PI negative; cells that are in early apoptosis are 
FITC Annexin V positive and PI negative; and cells that are in late apoptosis or already dead 
are both FITC Annexin V and PI positive. This assay does not distinguish between cells that 
have undergone apoptotic death versus those that have died as a result of a necrotic 
pathway because in either case, the dead cells will stain with both Annexin-FITC and PI.  
The 2×106 cells were collected after 48 hours of treatment and washed twice in phosphate-
buffered saline, then suspended in Annexin V binding-Buffer (0.1 M Hepes/NaOH (pH 7.4), 
1.4 M NaCl, 25 mM CaCl2. For a 1X working solution, dilute 1 part of the 10X Annexin V 
Binding Buffer to 9 parts of distilled water.), then supplemented with 2.5 μg Annexin V-FITC 
(FITC Annexin V,BD Pharmingen™,Heidelberg, Germany) and 5 μg PI (50 ug/ml, Fluka, 
Heidelberg, Germany). Samples were kept at 0°C for 15 min and then were analysed by flow 
cytometry (FACS Calibur System; BD Biosciences, Heidelberg, Germany). Fragments of 
damaged or apoptotic cells were determined as PI+ and Annexin V+ fraction using Flow 
Cytometry Analysis software (FlowJo). All experiments were performed in triplicate. 
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3.6 Radiosynthesis of FLT and FDG 
FLT was provided by Prof. H.-J. Wester according to a simplified labelling approach 
reported by Machulla et al (105). Before administration of the radiotracer, all mice were 
anesthesized with 4% isoflurane (Abbott GmbH, Wiesbaden, Germany) using a veterinary 
anesthesia System (Vetland Medical Sales and Services, Louisville, KY, USA). During PET 
imaging, the dose was reduced to 1.5% isoflurane. Imaging with FLT- or FDG-PET was 
performed using a dedicated small animal PET system (MicroPET, Focus 120, SIEMENS 
Preclinical Solutions, Knoxville, TN, USA). FLT or FDG/mouse (3.7–7.4 MBq) was injected 
intravenously, and data acquisition was started 45 min after the tracer administration. Data 
were acquired for 15 min. All acquisitions were done in listmode format and histogrammed 
into a frame sinogram. The sinogram was reconstructed into a 128×128×95 voxel image with 
filtered back projection method with a cut-off at the Nyquist frequency. The voxel size equals 
0.433×0.433× 0.796 mm3. Data were normalized and corrected for randoms, deadtime, and 
decay. Tumor-to-background ratios (TBR) were calculated to semi-quantitatively assess the 
tracer accumulation in the tumor. For this purpose, region of interest (3D-ROI) were manually 
placed over the tumor and corresponding regions of interest (ROIs) were drawn on the 
contralateral side of transaxial sections. The tracer uptake in latter region or mean tracer 
uptake in the two spinal muscles is defined as background.      
 
3.7 Cellular uptake of FLT and FDG 
5× 105 cells were cultured after 24hrs as above in 1ml DMEM with above described 
supplements in 9-well flat-bottom plates for inhibitor treatment. After treatment, cell cultures 
were moved to 1.5ml Eppendof-cups (Eppendorf AG, Hamburg, Germany) and 370KBq [18F]-
FLT or [18F]-FDG in 100 μl was added into the samples. After incubation at 37°C for 45 
minutes, the samples were washed with PBS for 3 times. The PBS must be completely 
removed in the end. The cells were then analyzed for radioactivity using an automated 
gamma-counter (Cobra II, Packard Instruments). Data were decay corrected and expressed 
as percentage of uptake / total activity administered. All experiments were performed in 
triplicate. 
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3.8 Western blot analysis 
2 × 106 cells were cultured as above in 3 ml DMEM with above described supplements for 
inhibitor treatment. After treatment, cells were washed twice in ice-cold PBS and were lysed 
in 150μl ice-cold lysis buffer containing one protease-inhibitor-tablet, 20% prime lysis buffer 
(5 times), 4% phosphate-buffer (pH 7.0), 20% Na-pyrophosphate (pH 7.0 – 7.5), 10% NaF-
buffer, 1% phenylmethylsulfonyl fluoride (PMSF) buffer and 1% orthovanadate (100mmolar) 
buffer. Whole cell lysates (130-150μl) were mixed with an equal volume of 2× loading buffer. 
The lysates and pre-stained molecular weight markers were heated for 15 min at 95°C and 
separated by 7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) at 160V per gel for 
4 hours or at 30 V for overnight. Then proteins were transferred to a PVDF membrane at 800 
mA for 60-90 min, depending on the protein weight. The membrane was blocked in Tris-
buffered saline containing 5% BSA or milk and 1%PBS-Tween-20 for 45 min. Concentrations 
of proteins were determined via the Bio-Rad Protein assay strictly following the 
manufacturer's instructions. Proteins (30-40 μg/lane) were separated on a denaturing 7.5% 
SDS polyacrylamide gel and transferred to a nitrocellulose membrane. Membranes were 
blocked in 5% BSA in phosphate-buffered saline (PBS) and subsequently incubated 
overnight at 4°C or 2 hours at room temperature with primary antibody. After three times 
washes, the membranes were incubated with secondary antibody against rabbit IgG or 
mouse IgG diluted 1: 10,000 in % PBS- Tween for 30min. to 45min. at room temperature. For 
detection of β-actin, the same membranes were incubated with mice polyclonal anti-beta 
actin antibody overnight at 4°C or 1h at room temperature and processed as described. 
3.8.1 Stock solution 
5x prime lysis buffer: 50 mM Tris-HCl, pH 7.4; 650 mM NaCl; 25 mM EDTA 
(ethylendiaminetetraacetic acid), pH 8.0; 5%Triton X-100 
5x Na-Pyrophosphat buffer (50 mM): pH 7.0-7.5: 2.66 g solubilised in 200 ml dist. water  
10x NaF (0.5 M): 4.2 g solubilised in 200 ml  
100x benzamidine (5 mM): 7.85 g equated in 50 ml isopropanol, and stored in -20°C  
100x PMSF (0.1 mM): 0.174 g equated in 10 ml isopropanol, and stored in -20°C 
100x orthovanadate (100 mM): about 5 mg solubilised in dist. Water 
Volume of dist. Water in ml = m(weight) in mg / 183 (mg/mmol) 
2x loading buffer: 10 ml DTT (dithiothreitol); 5ml Tris-HCl; 20 ml 10% SDS, 2.5 ml 1% 
bromphenolblue and 10 ml 100% glycerol 
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DTT (1M): 15.4 g dithiothreitol solubilised in 100 ml dist. Water  
Tris-HCl (1M): 12.1 g Tris solubilised in 100 ml dist. Water, pH set with HCl to 6.8 
10% SDS: 10 g SDS solubilised in 100 ml dist. Water  
1% bromphenolblue: 0.1 g bromphenolblue solubilised in 100 ml dist. water 
3.8.2 Gel electrophoresis 
 Stacking-gel buffer: 
o Acrylamide/Bis-acrylamide 
o Staking-gel buffer 0.5 M TRIS HCl pH 6.8 
6.05 g TRIS, 0.40 g SDS in 100 ml dist. water, pH- value setting with HCl  
o Dist. water  
o Temed ( Tetramethylethylenediamine) 
o  10% APS ( Ammoniumpersulfate) 
100 mg dissolved in 1 ml dist. water 
 Running-gel buffer: 
o Acrylamide/Bis-acrylamide 
o Running-gel buffer 1.5 M TRIS HCl pH 8,8 
91 g TRIS, 2 g SDS dissolved in 500 ml dist. water pH- value setting with HCl 
o Dist. water 
o Temed ( Tetramethylethylenediamine) 
o  10% APS ( Ammonium persulfate) 
100 mg dissolved in 1 ml dist. water 
For different applications, we need to change the desired percentage of acrylamide, make up 
30 ml of running gel by selecting one of the following percentages and mixing the ingredients 
shown below. Gel will polymerize fairly quickly after adding TEMED and APS, so they will not 
be added until the gel is been ready to pour. 
 Running-gel Solution 
 7% 10% 12% 15% 
H2O 15.3 ml 12.3 ml 10.2 ml 7.2 ml 
1.5 M Tris-HCl, pH 8.8 7.5 ml 7.5 ml 7.5 ml 7.5 ml 
20% (w/v) SDS 0.15 ml 0.15 ml 0.15 ml 0.15 ml 
Acrylamide/Bis-acrylamide 
(30%/0.8% w/v) 
6.9 ml 9.9 ml 12.0 ml 15.0 ml 
10% (w/v) ammonium persulfate (APS) 0.15 ml 0.15 ml 0.15 ml 0.15 ml 
TEMED 0.02 ml 0.02 ml 0.02 ml 0.02 ml 
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 Stacking-gel Solution (4% Acrylamide): 
H2O 3.075 ml 
0.5 M Tris-HCl, pH 6.8 1.25 ml 
20% (w/v) SDS 0.025 ml 
Acrylamide/Bis-acrylamide 
(30%/0.8% w/v) 
0.67 ml 
10% (w/v) ammonium persulfate (APS) 0.025 ml 
TEMED 0.005 ml 
 
 1x Running Buffer 
100 ml 10x Running- Buffer with dist. water QS to 1 l 
 10x Running- Buffer 
o 288 g Glycin 
o 60 g TRIS 
o 20 g SDS 
QS to 2l with dist. water 
 Precision Plus ProteinTM Standards Dual Color 
 
Transferring proteins to nitrocellulose membrane: “wet” or “semidry” apparatus 
 
 Wet transfer: 
o Disassemble gel casting plates so the gel is flat on one side or the other. 
o Using a clean razor, remove the stacking gel and clip the top right corner of 
the blot (according to the loading). 
o Using gloved hands and tweezers, quickly cut a piece of 0,45 mM Immobilon- 
P- PVDF- Membrane to the same size of the gel. 
o Pre-wet the membrane in Methanol 
o Cut four pieces of Whatman paper to the size of the membrane. 
o Assemble the ‘sandwich’ as below make sure the cassette is open with the 
black side down before assembly 
 Wet and place a Dacron pad nearest the hinge 
 Wet two pieces of Whatman paper, place on the Dacron pad 
 Put gel right-side-up and back-to-front on the filter paper 
 Place pre-wet membrane on top of gel, matching the clipped edge of 
gel with the clipped edge of the membrane 
 Place two more pieces of wet Whatman paper onto the filter 
 Wet and place the other Dacron pad on the top. 
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 Close and lock the cassette, place it into the electrode cassette and 
cover with trans-blotting buffer. 
o Add a stir bar and ice pack, and start transfer 
o Time and voltage of transfer will vary depending on the properties of the 
protein and the trans-blotting buffer used. 
 
 Continuous semidry transfer: 
o Disassemble gel-casting plates so the gel is flat on one side or the other. 
o Using a clean razor, remove the stacking gel and clip the top right corner of 
the blot (according to the loading). 
o Using gloved hands and tweezers, quickly cut a piece of 0,45 mM Immobilon- 
P- PVDF- Membrane to the same size of the gel. (measure the gel area in 
centimeters) 
o Pre-wet both the membrane in methanol 
o Cut 16 pieces of Munktell Grade 1 filter paper to the size of the membrane. 
o Assemble the apparatus as follows: 
 Soak 8 pieces of filter paper in trans-blotting buffer and make sure they 
are air bubble free on the anode plate. 
 Place the pre-wet nitrocellulose filter onto the stack 
 Place the pre-soaked gel onto the membrane 
 Place 8 more soaked pieces of filter paper on the gel. 
 Purge the stack of any air bubbles with a glass pipette. 
 Assemble the cathode plate and start the transfer 
o The equation to calculate the amperage for a 1 hour transfer is: 
 0.8 mA / cm2 gel. 
o After 1 hour, disassemble apparatus and western blot the membrane. 
 
 Trans-blotting buffer 
o 3.5 l dist. water 
o 1 l methanol 
o 0.5 l 10x Running Buffer 
 
3.8.3 Protein detection 
 Protein-solution: 
o Nonfat dried milk 5%, 1 g dissolving in 20 ml PBS/ TWEEN 
 1x PBS, 10 g dissolved in 1 l H2O 
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 0,1% TWEEN, 1 ml in 1000 ml PBS solution 
o BSA 5% 
1 g dissolved in 20 ml PBS/TWEEN 
o 200x Na-azide 
4% NaN3  2 g dissolved in 50 ml dist. water 
 Antibodies: 
o ALK 
o p-Tyrosine 
o Akt 
o p-Akt 
o STAT3 
o p-STAT3 
o P70 
o p-P70 S6K 
o anti-Log Rabbit 
o anti-log mouse 
 
Developing the blot using PIERCE chemiluminescence substrates (Supersignal) 
 Mix equal parts of “stable peroxide solution” (white bottle) and “luminol solution” 
(brown bottle). For a minigel filter, 1 ml of each is ample in a square petri dish. 
 Mix by swirling and allow the solution to come to room temp (~ 5 minutes) 
 Incubate washed membrane with developing solution for 1 minute, swirling constantly 
and keeping membrane covered with solution. 
 Place the membrane face down on a piece of saran wrap, and fold edges under to 
seal the membrane 
 Place the wrapped membrane into an X-ray film cassette and tape edges to hold in 
place. 
 In the dark room, expose film to the filter and develop using the automatic film 
processor. 
 In ambient light, mark the position of the mw markers on the autorad using a marker. 
The tape marks on the autorad can be used to align the membrane with the autorad. 
 
3.8.4 Developing solution 
 PICO- developing solution 
 Dura- developing solution 
 Femto- developing solution 
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3.8.5 Membrane stripping 
 Amido black destain 
o 100 ml methanol 100% 
o 100 ml acetic acid 100% 
o 800 ml dist. water 
 
3.8.6 Bio-Rad protein assay 
Prepare 6 dilutions of a BSA (bovine serum albumin) protein standard (Nr. 500-0007, Bio-
Rad Laboratories GmbH, Munich, Germany), which representative of protein solution to be 
test (the prime concentration of BSA protein standard is 3 mg/ml, it was diluted with distilled, 
deionized water to the concentration of 1.5, 0.75, 0.375, 0.188 and 0.094 mg/ml). 5 μl of 
distilled water, each BSA protein standard and protein lysis was pipetted into a clean and dry 
96-well flat-bottom plates, each sample was two times pipetted for double research. 200μl 
(Nr.500-0114) and 25 μl reagent mixture containing reagent A (Nr.500-0113, Bio-Rad 
Laboratories, Munich Germany) and reagent S (Nr.500-0115, Bio-Rad Laboratories, Munich 
Germany) was added to the sample-well. The mixture was incubated at room temperature for 
at least 5 minutes and measured absorbance at 595 nm using ELISA reader. The incubation 
of samples at room temperature should not more than 1 hour. 
 
3.9 Animal models and induction of lymphoma xenotransplants 
Six - to eight – week – old female immunodeficient mice (CB-17 SCID) were obtained 
from Charles River (Wilmington, MA, USA). Ten million (10×106) lymphoma cells (SUDHL-1 
or Karpas299) suspended in sterile PBS (100μl) were injected subcutaneously into the right 
shoulder region. All animal experiments were authorized by a regional government agency 
(Regierung von Oberbayern, licence number 55.2 – 1 – 54 2531 – 52-07). Tumor diameters 
were measured daily with a shifting calliper, and tumor volume was calculated as (length × 
width × width)/2. Treatment was performed when xenotransplants reached a tumor volume 
rang during 0.1 and 0.8 cm³. 
Additionally to xenotransplant models, transgenic models of lymphoma were used for 
monitoring of early and very-early response to treatment. Previously we have established a 
transgenic (Eμ-myc) lymphoma model representing an aggressive histology.  
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3.10 Therapeutic regimens 
 Groups of 20 mice each undergo with targeted drugs treatment. Response to therapy 
is valuated in respective groups starting 24hrs after initiation of treatment. Imaging and in 
vivo measurement of FLT- and FDG-uptake were performed at additional time points at d-1 
and d0; d+1 and d+2; d+5 and d+6; d+13 and d+14. With targeted drugs treatment was 
performed including HSP90 inhibitors (NVP-AUY922), PI3K inhibitors (BGT266) and mTOR 
inhibitors (RAD001). The NVP-AUY922 was diluted with 5% glucose to the concentration of 
50 μg/ml and stored in -80 °C for daily intraperitoneal (i.p.) injection using. Accordingly, the 
RAD001 was diluted with 5% glucose to the concentration of 10μg/ml, and the BGT266 was 
diluted with 0.01 M HCl to 1. 5 mg/ml. The treatment of RAD001 and BGT266 used the oral 
administration (p.o.) in daily and 4on/3off weekly administration. The control group received 
glucose solution (0.5%) only. 
 
3.11 Tumor immunohistochemitry 
The apoptosis and proliferation markers were used for the immunohistochemistry. 
Sample of the tumor xenografts were routinely fixed in 4% buffered formalin and embedded 
in paraffin, and then cut in 5 μm sections. The Immunostainer (Ventana medical Systems, 
Inc., Tucson, AZ, USA) was used according to the company s´ protocols, with slight 
modification. After deparaffinization and rehydration, the slide were placed in a microwave 
pressure cooker in 0.01 mol/l citrate buffer, pH 6.0, containing 0.1% Tween 20, and heated in 
a microwave oven at maximum power for 30 lr for 8 min. (hot start). Thereafter, sections 
were washed in Tris-buffered saline (pH 7.6) containing 5% fetal calf serum (Life 
Technologies, Grand Island, NY, USA) for 20 min. The primary antibodies were incubated 
overnight at room temperature. The anti-cleaved caspase 3 antibody was obtained from Cell 
Signaling (New England Biolabs, Frankfurt, Germany) and the monoclonal rabbit anti-Ki67 
antibody (clone SP6) from Lab Vision Corp (Fremont, CA, USA). The rest of the procedure 
was performed on the automated immunostainer, using diamino-beyzidine as chromogen.  
3.12 Paraffin section method and technique 
1. Fix tissues with 10% formalin or other fixatives for 24-48 hours at room temperature. 
Make sure you have enough fixative to cover tissues. Fixative volume should be 5-10 
times of tissue volume. 
2. Trim fixed tissues into appropriate size and shape and place in embedding cassettes. 
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3. Process for paraffin embedding schedule as follow (total 16 hours): 
o 70% Ethanol, two changes, 1 hour each 
o 80% Ethanol, one change, 1 hour 
o 95% Ethanol, one change, 1 hour 
o 100% Ethanol, three changes, 1.5 hour each 
o Xylene or xylene substitute (i.e. Clear Rite 3), three changes, 1.5 hour each 
o Paraffin wax (58-60 ºC), two changes, 2 hours each 
o Embedding tissues into paraffin blocks. 
4. Trim paraffin blocks as necessary and cut at 3-10 um (5 um is commonly used). 
5. Place paraffin ribbon in water bath at about 40-45 ºC. 
6. Mount sections onto slides. 
7. Allow sections to air dry for 30 min and then bake in 45-50 ºC oven overnight. NEVER 
allow baking temperature go higher than 50 ºC for sections thicker than 25um.  Otherwise 
sections may crack, especially 25-50 um thick sections, and result in sections falling off 
slides during staining. 
8. The deparaffinize sections in 2-3 changes of xylene, 10 min each. Use three changes of 
xylene for sections thicker than 25 um. 
9. Hydrate in 2 changes of 100% ethanol for 3 min each, 95% and 80% ethanol for 1 minute 
each. Then rinse in distilled water. 
 
3.13 Statistical methods 
 GraphPad Prism 5 (GraphPad Software, Inc, La Jolla, CA, USA) software Excel 2007 
(Microsoft) was used for statistical analysis. Mean values, median, and standard deviation of 
tumor size and TBR in controls and treated mice were calculated. Tumor sizes were log-
transformed to estimate the slope of log-linear tumor growth. The paired T test was used to 
test for signification changes between two related measurements. Unpaired T test was used 
to test for differences of tumor size and tumor growth rates between two independent mice 
groups. Furthermore, linear mixed regression models were calculated to confirm the results 
of univariate analysis, regarding for dependency of repeated measurements within the same 
individual. A p value, lower than 0.05, was considered as statistically significant. 
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4 Results 
4.1 Dual inhibition of AKT and mTOR blocks the proliferation of multiple 
NPM-ALK lymphoma cell lines 
4.1.1 Dual blockage of AKT and mTOR affects the viability of ALK+ lymphoma 
cells  
 
Based on preclinical research from Novartis, BGT226 inhibits proliferation and colony 
formation in tumor cell lines / tumor stem cells of glioblastroma multiforme (GI50=4.5-12 nM), 
breast cancer (GI50= 1.1-4.9 nM), prostate cancer (GI50= 6.1-8 nM), NSCLC (GI50= 4.1 nM), 
colorectal cancer (GI50= 12 nM) and ovarian cancer (GI50= 7.8 nM). To assess the 
biological effect of BGT266 on lymphoma cell survival, we performed MTT assays on 
SUDHL-1, BaF3-NPMAL and Karpas299 cells incubated with increasing concentrations of 
drug for 24 hours and 48 hours (Figs. 3A-3F). SUDHL-1 and BaF3-NPM-ALk cells showed a 
dose-dependent decrease in the cell viability, while Karpas299 cells showed partially 
resistance to BGT266 treatment. Although the lower concentration (0.1 nM) of BGT266 had 
no effect on cell proliferations, it remarkable inhibited proliferation of SUDHL-1 cells in a dose 
dependent manner. The SUDHL-1 cell viability was reduced from 96.1% (0.1 nM) to 14.1% 
(100 nM) with BGT226 treatment for 24 hours (Fig. 3B). Additionally, after treatment SUDHL-
1 cells were dramatically inhibited. No surprisingly, BGT226 also reduced the cell viability in 
time-dependent manner. Taking SUDHL-1 cell line as an example, a 50% inhibition of the 
cell viability was first detected with a dose of 10nM after 24 hours incubation (Fig. 3B), but 
decreased to 1 nM after the 48 hours treatment with BGT226 (Fig. 3E). Similar results were 
also found in BGT266 treated BaF3-NPMALK cells, and a 50% inhibition rate was detected 
with a dose between 1 and 10 nM as early as 24 hours after treatment. Moreover, the 
inhibition rate rose to 75% after treatment with a dose of 100nM (Fig. 3C). However, an 
effective inhibition of the karpas299 cells viability was only found with a concentration of 100 
nM after treatment with BGT226 (Fig. 3A and 3D). 
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Fig. 3: PI3K/mTOR inhibitor BGT226 inhibits the cell viability in the time and dose dependent 
Manner. Cells were treated with the indicated concentration of BGT226 for 24 hours and 48 
hours. The bars represent the mean ± SD of the mean from n=3 experiments. 
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4.1.2 Dual inhibition of AKT and mTOR activity induces the cell cycle arrest of 
ALK+ lymphoma cells 
 
We examined the effects of BGT266 on cell cycle progression. BGT266 led to an increase in 
the percentage of cells in the SubG1/G1 phase compared to control conditions in SUDHL-1 
cells (Fig. 4B and E). The results showed that BGT226 arrested SUDHL-1 lymphoma cells in 
the original G1 phase (from 41.1% in control to 71.3% at 100 nM), while reduced cells in the 
S phase (from 25.8% in control to 4.6% at 100nM). The percentage of dead cells rose from 
7.8% to 22.4% flowing dose of 100 nM as early as 24 hours (Fig. 4B). At 48 hours, cell 
percentage was reduced about 30% (from 30.7% to 1.9% at 100 nM) from S phase and the 
cells traversed to the G1 phase (from 44% in control to 60% at 100 nM) and the SubG1 (from 
3.9% to 23.7% at 100 nM) (Fig 4E). There was no change in the SubG1 phase indicating 
apoptosis during treatment with BGT226 in Karpas299 cells (Fig. 4A and D), and only a slight 
increase in the G1 Phase was detected from 32% to 49% with a dose of BGT226 at 100 nM 
after 48 hours incubation (Fig. 4D). Compared with SUDHL-1 cells experienced a S Phase 
reduction of 30%, Karpas299 cells only decreased from 32% to 16% (48 hours, 100 nM) in 
the S phase, while the Karpas299 cells in S phase decreased minimal from 22% in control 
reaching a value of 16% at 100 nM dosage after 24 hours of the treatment period (Fig. 4A). 
After 24 hours incubation with 100 nM BGT266 in BaF3-NPMALK cells, BGT226 caused a 
G1 phase arrest (from 50% to 77%), a reduction of the S phase (11%) and the G2 phase 
(14%) and a slight increase of cell death. However, we found no reduction of the S phase 
during treatment with 10 nM BGT226 (Fig. 4C). At 48 hours, the cell percentage was reduced 
from 19% to 12% at 100 nM in the S phase and the cells traversed to the G1 phase with 10% 
at 10 nM. There was no marked increase in the Sub G1 phase (Fig. 4F). 
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Fig. 4: PI3K/mTOR inhibitor BGT226 induces the cell cycle arrest (G1-phase) and apoptosis 
in ALCL lymphoma cells. Cells were treated with the indicated concentration of BGT226 for 
24 hours and 48 hours. The bars represent the mean ± SD of the mean from n=3 
experiments. 
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4.1.3 Down-regulation of several oncogenic proteins during exposure of human 
lymphoma cells to PI3K/mTOR inhibitor 
 
BGT226 is a pan-class I PI3K and mTOR inhibitor. To further investigate the effect of 
BGT226 on the PI3K/AKT and mTOR signalling pathways, all cell lines were treated with 
BGT266 in 0, 1, 10 and 100 nM for 16 hours and / or 8 hours. As shown in Fig. 5A to Fig. 5C, 
BaF3-NPMALK, SUDHL-1 and Karpas299 cells were selected to investigate concentrations 
and time effect of BGT226 on PI3K/mTOR signalling pathways. The expression levels of p-
AKT and p-STAT3 were decreased in BaF3-NPMALK and SUDHL-1 cells as early as 8 
hours after treatment with BGT226 flowing a dose of 10 nM (Figs. 5A and B). In contrast, no 
change of oncoprotein expression was found up to 16 hours incubation with BGT226 in 
Karpas229 cells (Fig. 5C). The mammalian target of rapamycin (mTOR) is a serine/threonine 
protein kinase belongs to the PI3K protein family regulating cell growth, cell proliferation, cell 
motility, cell survival, protein synthesis and transcription. And mTOR Complex 1 (mTORC1) 
is composed of mTOR, regulatory associated protein of mTOR (Raptor) and p70-S6 Kinase 
(p70-S6k). The p70-S6k is one of the best characterized targets of mTORC1. Thus, the 
change of p-p70-S6k during the treatment in BaF3-NPMAL cells was observed 8 hours after 
incubation with inhibitor. As shown in Fig. 5A, compared to control, p-p70-S6k was strongly 
inhibited with a 1 nM BGT266 treatment as early as 8 hours. 
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Fig. 5: PI3K/mTOR inhibitor BGT226 inhibits expression of several oncoproteins in ALCL 
lymphoma cells (A: BaF3-NPMAL cells, B: SUDHL-1 cells, C: Karpas299 cells). Cells were 
treated with the indicated concentration of BGT226 for 8 hours and/or 16 hours. 
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4.2 Functional in vivo imaging of response to PI3K/mTOR (BGT226) 
inhibition in SUDHL-1 lymphoma by FLT-PET is superior to FDG-PET 
4.2.1 Blockage of PI3K/mTOR activity decrease the tumor growth of NPM-ALK 
lymphoma in vivo 
 
To evaluate FDG- and FLT-PET imaging for early response monitoring in vivo, we generated 
xenograft SUDHL-1 and Karpas299 tumors. To mimic the clinical situation, the treatment was 
initiated once the tumor volume reached approximately 500mm³. In SUDHL-1 bearing mice, 
the control group showed a 6.3-fold (n=3, SD=0.6, range 5.7-6.9-fold) increase of tumor 
volume (Fig. 6A). The tumors of BGT226-treated mice had a 2.1-fold increase at d+7 (n=6, 
SD=0.66, range 1.3-2.8-fold). Until d+14, tumors of the therapeutic group remained nearly 
constant during the observation period (n=6, mean 2.2-fold increase, SD=0.65, range 1.2-
2.9-fold). In contrast, the tumor volume of the controls increased to 12.2-fold (n=3, SD=2.2, 
range 9.9-14.2-fold) at d+14. During the tumor growth of SUDHL-1 bearing mice treated with 
BGT226, there was no remarkable Inhibition effect on Karpas299 tumor growth (Fig. 6b). The 
therapeutic group showed a 3.3-fold (n=9, SD=1.1, range 1.8-4.6-fold) increase in tumor 
volume and the tumors of the control mice had a 3.5-fold increase at d+7 (n=7, SD=1.1, 
range 2.7-5.8-fold). The tumor volume of the control group continuously increased to 5.7-fold 
(n=3, SD=1.3, range 5.7-7.8) and to 6.1-fold in the therapeutic group (n=4, SD=0.6, range 
5.2-6.6-fold) at d+14. 
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Fig. 6A: BGT226 blocks the SUDHL-1 tumor growth. The SUDHL-1 lymphoma bearing mice 
were treated oral with 7.5 mg/kg BGT226 (Therapy)or only placebo(Control) three times pro 
week. The bars represent the mean ± SD. 
 
 
Fig. 6B: Karpas229 lymphoma shows resistant to BGT226 therapy. The karpas299 
lymphoma bearing mice were treated oral with 7.5 mg/kg BGT226 (Therapy) or only placebo 
(Control) three times pro week. The bars represent the mean ± SD. 
 
4.2.2 FDG-PET imaging analysis shows inhibitory effect of PI3K/mTOR on the 
NPM-ALK lymphoma metabolism  
 
To investigate SUDHL-1 and Karpas299 lymphoma in response to BGT226 treatment, FDG-
PET was performed both before and after therapy at d-1, d+8 and d+13 (Fig. 7A and 7B). In 
SUDHL-1 lymphoma bearing group, the mean TBR of treated mice with dose of 7.5 mg/kg 
reduced from 8.1 (at d-1: n=7, range 4.0-11.4, SD= 5.7) to 7.0 (at d+8: n=7, range 4.0-7.7, 
SD= 1.7) and then to 5.2 (at d+12: n=6, range 4.5-6.3, SD=0.7). The mean TBR of untreated 
mice was increased from 5.7 (at d-1: n= 4, range 4.0-7.7, SD= 1.2) to 7.0 (at d+8: n=4, range 
5.2-8.4, SD= 1.6). The mean TBR ended at 6.5 (n=3, range 5.6-7.1, SD= 0.8) until d+14. 
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In karpas299 lymphoma bearing group, the mean TBR of treated mice increased from 4.7 at 
d-1 (n=4, range 3.1-6.2, SD=1.3) to 6.1 (n=4, range 4.4-9.9, SD=2.6) at d+8, and remained 
no reduction with 6.2 (n=3, range 5.0-7.0, SD=1.1) until d+13. The mean TBR of the controls 
increased from 6.5 (at d-1: n=4, range 4.3-8.7, SD=1.8) to 7.2 (n=4, range 6.3-8.0, SD=0.9) 
at d+8, but then went down to 5.2 (n=4, range 4.5-6.3, SD=0.7) at d+13 (Fig. 7B). 
 
 
Fig. 7A: BGT226 treatment reduces the FDG-tracer-uptake in SUDHL-1 lymphoma. The 
SUDHL-1 lymphoma bearing mice were treated oral with 7.5 mg/kg BGT226 (Therapy) or 
only placebo (Control) three times pro week. The bars represent the mean ± SD. 
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Fig. 7B: No remarkable reduction of FDG-tracer-uptake was found in Karpas299 lymphoma 
under treatment with BGT226.The karpas299lymphoma bearing mice were treated oral with 
7.5 mg/kg BGT226 (Therapy) or only placebo (Control) three times pro week. The bars 
represent the mean ± SD. 
 
4.2.3 FLT-PET imaging analysis shows inhibitory effect of PI3K/mTOR on the 
cellular proliferation of NPM-ALK lymphoma  
 
As a more tumor specific tracer, FLT was also applied to detective the therapeutic response 
in lymphomas during BGT226 treatment. SUDHL-1 and Karpas299 bearing mice were 
scanned with FLT-PET both before and after therapy at d-1, d+2, d+7, and d+14, 
respectively. Figs. 8a and 8b showed representative TBRs of different therapeutic groups. A 
remarkable decrease of the FLT-uptake in SUDHL-1 bearing mice can be detected two 
weeks after therapy with 7.5 mg/kg BGT226 (n=6, pre-therapeutic uptake: mean TBR= 2.9, 
range 2.3-4.7, SD=0.7; post-therapeutic uptake: mean TBR=1.3, range 1.0-1.7, SD=0.2) (Fig. 
8A). In contrast, the FLT-uptake remained no change in the control mice (n=3, pre-
therapeutic uptake: mean TBR= 2.6, range 1.9-2.7, SD=0.5; post-therapeutic uptake: mean 
TBR=2.6, rang 2.7-3.6, SD=0.7). The FLT-uptake decreased only slightly until d+7. The 
mean TBR of the therapeutic mice was 2.4 (n=6, range 1.9-2.8, SD=0.6), and the mean TBR 
in control mice increased slightly to 2.9 (n=3, range 2.1-3.4 SD=0.1) at d+7. The FLT-PET 
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was also performed on AUY922 resistant Karpas299 lymphoma bearing mice with a dose of 
25 mg/kg. The mean TBR of the therapeutic group increased from 3.5 (n=8, range 2.6-4.1, 
SD=0.6) to 5.8 (n=4, range 4.2-6.8, SD=1.1) at d+2, and remained with 5.0 (n=4, range 3.6-
6.0, SD=1.0) at d+7 (Fig. 8B). The mean TBR of FLT-uptake in therapeutic karpas299 
lymphoma was reduced to 3.7 (n=4, range 3.3-4.1, SD=0.4) at d+14. In controls, the mean 
TBR was also increased from 4.3 (n=7, range 2.3-6.3, SD=1.4) to 5.4 (n=3, range 4.9-6.1, 
SD=0.6) at d+2, remained no change until d+7 (n=3, mean=5.2, range 4.8-5.8, SD=0.5) and 
then reduced to 4.1 (n=4, range 3.1-4.7, SD=0.7) at d+14. 
 
 
Fig. 8A: BGT226 treatment reduces the FLT-tracer-uptake in SUDHL-1 lymphoma. The 
SUDHL-1 lymphoma bearing mice were treated oral with 7.5 mg/kg BGT226 (Therapy) or 
only placebo (Controls) three times pro week. The bars represent the mean ± SD. 
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Fig. 8B: No remarkable reduction of FLT-tracer-uptake was found in Karpas299 lymphoma 
under treatment with BGT226.The karpas299lymphoma bearing mice were treated oral with 
7.5 mg/kg BGT226 (Therapy) or only placebo (Controls) three times pro week. The bars 
represent the mean ± SD. 
To analyse the predictive value of early functional imaging for response assessment, the 
statistical analyses were also done in this work. We performed FDG- and FLT-PET scans 
using a micro PET/CT system before, one and two weeks after initiation of BGT226 
treatment (Fig. 9A). To do so, the change of TBR after therapy was compared to pre-
treatment TBR, which was defined as 100%, was calculated (relative TBR). FDG-PET 
analysis of control animals revealed a significant increase in FDG-uptake on day 8 (n=3, 
mean TBR 138.3%, range 118.4%-133.4%, SD=13.2%, p=0.01, Fig. 11B right) and day 13 
(n=3, mean TBR 120.8%, range 106.1%-143.4%, SD=19.9%, p=0.01, Fig. 9B). In BGT226 
treated animals, relative TBR of early FDG-PET showed a significant reduction compared to 
the pre-treatment control (n=6, mean TBR 91.1%, SD=23.1%, range 63-129.5%; p=0.3). 
Interestingly, the mean TBR of FDG-uptake at later time points (day 14) decreased to 74% 
(n=3, SD=23.1%, range 49.9-96.4%; p=0.04). At the same time, the relative mean TBR of 
FLT-uptake decreased also not significantly to 92.5% compared to baseline (n=6, SD=37.5%, 
range 54.8-119.3%, p=0.3) at d+6 after initiation of therapy (Fig. 9C). The relative TBR of 
untreated controls increased to 122% during the same time period (n=3, range 99.9%-151%, 
SD=26%, p=0.02). Later time points within the treatment group (day 8 to 14) showed a 
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further significantly reduction in FLT-uptake with p value of 0.002 (n=6, mean=50.6%, range 
38.7%-69.9%, SD=19.7%). 
 
 
Fig. 9A: Functional in vivo imaging of response to BGT226 inhibition in SUDHL-1 lymphoma 
using FLT- and FDG-PET 
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Fig. 9B: Determination of FDG-TBR in percentage by comparison with baseline (TBR from 
pre therapy PET) in control SUDHL-1 lymphoma and TBR on day 0, defined as 100% (“pre”). 
The bars represent the mean ± SD. 
 
Fig. 9C: Determination of TBR in percentage by comparison with baseline (TBR from pre 
therapy PET) under BGT226 treatment in SUDHL-1 lymphoma and TBR on day 0, defined 
as 100% (“pre”), and change of TBR compared to pre-treatment values are shown for treated 
(“post”) (left: after one week; right: after two weeks).The bars represent the mean ± SD. 
 
4.2.4 Histological analysis shows decreased proliferation and increased 
apoptosis induced by the treatment with PI3K/mTOR inhibitor in NPM-ALK 
lymphoma 
 
To correlate the PET findings with treatment effects of inhibitors on SUDHL-1 xenograft 
lymphomas, we stained fixed tumor sections with the proliferation marker Ki-67 and the 
cleaved caspase-3 to analyse the apoptosis. BGT226 treatment led to a significant increase 
in apoptosis quantified using cleaved caspase-3 positive cells (Fig. 10A, n=4, mean 6.8%, 
SD=5.3%) compared to untreated mice (n=4, mean 1.7%, SD=1.3%). Moreover, the 
percentage of proliferating cells was substantially decreased by BGT226 as measured using 
Ki67 staining with a mean of 14.2% (SD=7.5%) in the treated and 63.6% (SD=20.3%) in the 
control tumors.  
The PET findings of Karpas299 lymphomas were confirmed by immunohistochemistry as 
showed in Fig. 9B. No remarkable increase of the apoptosis was detected after BGT226 
treatment compared to the control tumors (controls: n=3, mean=1.4%, SD=1.3%; therapeutic 
group: n=5, mean=1.1%, SD=0.8%). BGT226 only led to a slight reduction of proliferation in 
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karpas299 lymphomas using Ki67 staining (therapeutic group: mean=43.5%, SD=18.2%; 
controls: mean=54%, SD=23.9%). 
A 
 
B 
 
Fig. 10: BGT226 treatment triggers a cell death (marker: caspase-3) and a reduction of 
proliferation (marker: Ki-67)in SUDHL-1 but not in karpas299 lymphoma in vivo (A: SUDHL-1 
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lymphoma, B: karpas299 lymphoma). The lymphoma bearing mice were treated oral with 7.5 
mg/kg BGT226 (Therapy) or only placebo (Controls) three times pro week. 
To correlate the PET findings with the treatment effects of BGT226 on SUDHL-1 xenograft 
lymphomas, the histological results were analysed using the Graphpad system (Fig. 11). 
BGT226 treatment led to a significant increase in apoptosis as quantified by cleaved 
caspase-3 positive cells compared to untreated mice (p=0.02, Fig. 12). Moreover, the 
percentage of proliferating cells was substantially decreased by BGT226 as measured by 
Ki67staining with a mean of 15.3% for the treated and 63.3% for the control tumors (p=0.02). 
Taken together, both FDG as well as FLT-uptake correlates with response to HSP90 
inhibition in vivo. However, FLT-PET is as good as FDG-PET for early in vivo response 
assessment that precedes change of tumor volume to PI3K/mTOR-NPM-ALK-targeted 
treatment. 
 
Fig. 11: Histological assessment of BGT226 effect on SUDHL-1 lymphoma in using 
proliferating marker Ki-67 and apoptotic cell death marker caspase-3. The bars represent the 
mean ± SD. 
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4.3 Inhibition of Hsp90 blocks the proliferation of multiple ALK+ 
lymphoma cell lines 
4.3.1 The blockage of Hsp90 activity affects the viability of ALK+ lymphoma 
cells   
 
Active mitochondria of living cells can cleave MTT to produce a purple-blue formazan, whose 
intensity indicates the number of living cells. To assess the biological effect of NVP-AUY922 
on the survival of lymphoma cells, we performed MTT assays on BaF3-NPMALK, BaF3-
parental, JB-6, SUDHL-4, Karpars299 and SUDHL-1 cells which were incubated with 
increasing concentrations of the drug for 24, 48 and 72 hours (Fig.12). All cell lines showed a 
dose-dependent decrease in cell viability. Karpas299 cells were less sensitive than the other 
cell lines to the catatonic activity of NAP-AUY922 after 48 hours of treatment, while the JB-6 
was slightly more resistant.  
Although lower concentration (1 nM) of NVP-AUY922 had no effect on cell viability within a 
24 hours of incubation period, the inhibition rate was 20% at a dose of 10 nM in BaF3-
NPMALK and BaF3-parental cells, respectively. It increased to 50% and 20% at the dose of 
100 nM (Fig. 12A and 12D). In contrast, there was only a slight reduction of viability in JB-6 
and SUDHL-4 cells (Fig. 13A and 13D). At the dose of 10 nM, the viability of SUDHL-1, as 
well as of Karpas299, was reduced to 70% (Fig. 14A and 14D). After a 48 hours incubation, 
a dose of 10 nM caused a 40% reduction of the viability in BaF3-NPMALK cells and the 
reduction was increased to 70% under treatment with 100 nM (Fig. 12B). Interestingly, there 
were almost no survival BaF3-NPMALK cells after a 72 hours treatment with AUY922 (Fig. 
12C). Compared to other cell lines, 10 nM AUY922 reduced BaF3-Parental and SUDHL-4 
survival rate to 70% (Fig. 12E and 13E) and the viability of SUDHL-1 cells was reduced to 20% 
under treatment with 50 nM AUY922 after a 48 hours incubation (Fig. 14E). After 72 hours 
almost all SUDHL-1 ceased proliferation (Fig. 14F). However, the JB-6 cells showed limited 
reduction of the cellular proliferation up 72 hours (Fig. 13C). In contrast, IC50 of Karpas299 
cells was also found after a 72 hours of an incubation period with a drug dose of 100 nM (Fig. 
14C).These findings were also confirmed by the observed cell cycle and apoptosis assay. 
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Fig. 12: Hsp90 inhibitor NVP-AUY922 inhibits the cell viability in the time and dose 
dependent Manner in BaF3-NPMALK and BaF3-parental cells. Cells were treated with the 
indicated concentration of AUY922 for 24 hours, 48 hours and 72 hours. The bars represent 
the mean ± SD of the mean from n=3 experiments. 
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Fig. 13: Hsp90 inhibitor NVP-AUY922 inhibits the cell viability in the time and dose 
dependent Manner in SUDHL-4 cells, but JB-6 cells shown partially resistant to AUY922 
treatment. Cells were treated with the indicated concentration of AUY922 for 24 hours, 48 
hours and 72 hours. The bars represent the mean ± SD of the mean from n=3 experiments. 
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Fig. 14: Hsp90 inhibitor NVP-AUY922 inhibits the cell viability in the time and dose 
dependent Manner in SUDHL-1 cells, but karpas299 cells shown partially resistant to 
AUY922 treatment. Cells were treated with the indicated concentration of AUY922 for 24 
hours, 48 hours and 72 hours. The bars represent the mean ± SD of the mean from n=3 
experiments. 
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4.3.2 Inhibition of Hsp90 activity triggers the cell cycle arrest and apoptosis of 
ALK+ lymphoma cells 
 
At nanomolar concentrations, NVP-AUY922 inhibits in vitro proliferation of human tumor cells 
selected for their different tissue origins and molecular features. We have studied the effect 
of NVP-AUY922 treatment for 24 hours, 48 hours and 72 hours on cell cycle of BaF3-
NPMALK, BaF3- parental, JB-6, SUDHL-1 and Karpas299 lymphoma cells. The cell cycle 
was detected using the PI-staining FACS assay. NVP-AUY922 induced accumulation in 
either the G1 or the G1 plus G2/M phase in most of the investigated cell lines. The results 
showed that NVP-AUY922 arrested SUDHL-1 lymphoma cells in the original G1 (from 43.4% 
in control to 58.7% at 50 nM), while the S phase reduction was observed (from 29% in 
control to 4.5% at 50 nM) as early as 24 hours (Fig.16D). After a 48 hours of the treatment 
period, cells in the S phase (from 27.1% in control to 10.2% at 50 nM) traversed to the G1 
phase (from 50.2% in control to 64% at 50 nM) remained blocked over 72 hours (Fig. 16E 
and F). The Cells traversed to the subG1 phase (from 5.2% in control to 43.8% at 50 nM) 
from the G1 phase (from 57.5% in control to 42.2% at 50 nM) and the S phase (from 29.6% 
in control to 4.6% at 50 nM) indicated apoptosis (Fig. 16E). Upon treatment with NVP-
AUY922, BaF3-NPMALK demonstrated an increase in the percentage of cells accumulating 
in the G1 phase (from 14.6% in control reaching a peak value of 44.2% at 50 nM dosage) 
and the G2 phase (from 19.7% in control reaching a peak value of 28.2% at 50 nM dosage). 
The cells of the S phase decreased (from 58.8% in control reaching a value of 18.4% at 50 
nM dosage) from 24 hours untill 48 hours (Fig. 15A and B). After a 72 hours treatment with 
the drug, the cells traversed to the sub G1 phase (from 8.25% in control reaching a peak 
value of 60.39% at 50 nM dosage) from the G1 phase (from 24.7% in control to 7.6% at 50 
nM dosage), the S phase (from 58.8% in control reaching to 8.2% at 50 nM dosage) and the 
G2 phase (from 19.7% in control to 6.4% at 50  nM dosage) (Fig. 15C). However, treatment 
of Karpas299 cells with NVP-AUY922 induced a therapeutic resistance (Fig. 16A-B). 
Inhibition of the S phase was detected only with 1% of karpas299 cells (from 18.3% to 17.9%) 
at a 50 nM dosage, compared with 15% in SUDHL-1 cells. After a 24 hours treatment with 
NVP-AUY922, only a slight change of the G1 and the G2 phases for Karpas299 cells was 
found during the incubation time up to 72 hours (Fig. 16A). The cell cycle of BaF3-Parental 
and BaF3-NPMALK cells changed in a similar way (Fig. 15A-B). 
To determinate the NVP-AUY922 induced apoptosis we have studied the effect of NVP-
AUY922 treatment 48 hours BaF3-NPMALK, Karpas299, SUDHL-1, SUP-M2 and SR-786 
lymphoma cells. The results showed that NVP-AUY922 caused the remarkable cell death in 
BaF3-NPMALK, SUDHL-1, SUP-M2 and SR-786 lymphoma cells but not in Karpas299 
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lymphoma cells (Fig. 17 and 18). BaF3-NPMALK and SUP-M2 cells showed more sensitive 
to NVP-AUY922 treatment than other cells, with almost 100% cell death after 48 hours 
incubation at a 50 nM dosage of NVP-AUY922 (Fig. 17A and 18A). The dead cells increased 
from 5% to 40% after 48 hours treatment period with NVP-AUY922 (dosage: 50 nM) in 
SUDHL-1. Although are the SR-786 less sensitive to NVP-AUY922 treatment than BaF3-
NPMALK or SUP-M2 cells. But the NVP-AUY922 still caused a 60% death in SR-789 cells 
after 48 hours incubation (Fig. 18B).  As showed in Fig. 17B is there no remarkable cell 
death in Karpas299 cells after NVP-AUY922 treatment, means that Karpas299 cells are 
resistant to NVP-AUY922 treatment in vitro. PI-FACS was also done on SUP-M2 and SR-
789 lymphoma cells to determine the cell cycle arrest. No surprisingly, NVP-AUY922 arrests 
both SUP-M2 and SR-789 lymphoma cells in SubG1 phase (Fig.18).  
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Fig. 15: Hsp90 inhibitor NVP-AUY922 induces the cell cycle arrest (G1-phase) and 
apoptosis in BaF3-NMPALK and BaF3-parental lymphoma cells. Cells were treated with the 
indicated concentration of AUY922 for 24 hours, 48 hours and 72 hours. The bars represent 
the mean ± SD of the mean from n=3 experiments. 
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Fig. 16: Hsp90 inhibitor NVP-AUY922 induces the cell cycle arrest (G1-phase) and apoptosis 
in SUDHL-1 lymphoma cells, but karpas299 shown resistance to AUY922 treatment. Cells 
were treated with the indicated concentration of AUY922 for 24  , 48hours and 72 hours. The 
bars represent the mean ± SD of the mean from n=3 experiments. 
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Fig. 17: Hsp90 inhibitor NVP-AUY922 induced an apoptosis in ALCL cells (A: BaF3-NPMAL 
cells, B: Karpas299 cells, C: SUDHL-1 cells) as determined using Annexin V-FACS. Cells 
were treated with the indicated concentration of AUY922 for 48 hours. The bars represent 
the mean ± SD of the mean from n=3 experiments. 
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Fig. 18: The Hsp90 inhibitor NVP-AUY922 induced apoptosis in ALCL cells (A: SUP-M2 cells, 
B: SR-786 cells) as determined using Annexin V and PI-FACS. Cells were treated with the 
indicated concentration of AUY922 for 48 hours. The bars represent the mean ± SD of the 
mean from n=3 experiments. 
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4.3.3 Down-regulation of several oncogenic proteins during exposure of human 
lymphoma cells to Hsp90 inhibitor 
 
NPM-ALK is a constitutively active fusion tyrosine kinase involved in lymphomagenesis of 
ALCL cells, whose maturation and activity depend on their association with a Hsp90 protein 
chaperone. Targeting Hsp90 by NVP-AUY922 promotes degradation of several proteins 
through ubiquitin-proteasome pathways, including oncogenic AKT, STAT3 and p70S6K. 
NPM-ALK expression is down-regulated in lymphoma cells by NVP-AUY922. To study the 
effect of NVP-AUY922 on expression of NMP-ALK, several cell lines characterized 
previously by the presence of the t(2;5) translocation were chosen as experimental models, 
including BaF3-NPMALK, SUDHL-1 and Karpas299, and their proteins were analysed using 
Western blotting. The lymphoma cells were maintained in log phase growth and treated with 
different concentrations of NVP-AUY922 for 4 hours, 8 hours, 24 hours or 48 hours (Figs. 19 
to 20). Cells were lysed and ALK proteins were detected using an antibody ALK, which is 
specific for the cytoplasmic region of mature ALK.  
As shown in Fig. 19A, the ALK protein only began to change after a 24 hours treatment in all 
cell lines. Tyrosine-phosphorylated ALK proteins were detected with p-tyrosine antibody. The 
cell lines all responded to the NVP-AUY922 treatment. The p-tyrosine decreased 
proportionally to the increase of the NVP-AUY922 concentrations. In comparison with control 
cells, the reduction of proteins in SUDHL-1 cells reached 50%, when exposed to 25 nM NVP-
AUY922. No phosphorylation of the ALK protein could be detected above a dosage of 50 nM. 
Remarkably, a decrease in ALK protein was observed after the incubation with AUY922 for 
48hous (Fig. 19B). Moreover, Fig. 19B shows the complete inhibition of ALK above AUY922 
concentrations of 50 nM. However, there was still no significant decrease in ALK protein or 
phosphorylation of ALK protein found in Karpas299 cells. Recruitment and phosphorylation 
of downstream effected proteins require NPM-ALK dimerization and auto-phosphorylation. 
Thus, we measured levels of tyrosine-phosphorylated ALK in cells exposed for 24 hours and 
48 hours to NVP-AUY922 with different concentrations. Proteins, known not to be Hsp90 
client proteins, including β-actin, did not show any decrease in expression. This is consistent 
with the idea that the responsiveness of these cells to NVP-AUY922 is a result of the 
degradation of Hsp90 client proteins. Changes in phosphorylation states of signalling protein 
p-Tyrosine were shown in Figs. 19A and 19B. These decreases in phosphoproteins could 
result from either a decrease in baseline quantities of the non-phosphorylated versions of 
ALk proteins, or from the degradation of upstream proteins, which normally phosphorylate 
ALK and Tyrosine. We also found that reduction of ALK and p-Tyrosine levels in BaF3-
NPMALK cells could be observed as early as the 8 hours incubation with AUY922 (Fig. 19B). 
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Upon exposure to NVP-AUY922, NPM-ALK proteins have shown to be down-regulated in the 
human lymphoma cells. Additionally, NPM-ALK mediates oncogenesis, at least partially, 
through phosphorylation and / or activation of phosphatidylinositol 3-kinase (PI3K), the 
serine/threonine kinase AKT/mammalian target of rapamycin, Janus kinase/signal 
transducers and activators of transcription pathways, resulting in cell proliferation and anti-
apoptotic signals (11). Therefore, AKT kinase is the prominent downstream target of PI3K 
and one of important protein part in the Hsp90 pathway. AKT is also a critical regulatory 
compound in many signalling pathways.  
Upon administration of NVP-AUY922, AKT has proved to be down-regulated in BaF3-
NPMALK and SUDHL-1 cell lines in a dose- and time-dependent manner (Fig. 19A and 19B). 
NVP-AUY922 reduced AKT proteins in BaF3 cells after only an 8 hours treatment (Fig. 20). 
Then a 100% inhibition of AKT protein expression was detected in a dosage of 50 nM after 
24 hours of treatment period. The resistance of the Karpas299 to NVP-AUY922 was also 
observed through AKT western blotting. Next, we tested for presence of phosphorylated AKT 
in the same cells both before and after NVP-AUY922 treatment. In SUDHL-1 and BaF3-
NPMALK cell lines, AKT phosphorylation showed a dose-dependent decrease. The reduction 
resulted in an almost total elimination of the active form of protein with drug concentrations 
above 50 nM in both cell lines after a 24 hours treatment with NVP-AUY922 and with drug 
concentrations above 25 nM after 48 hours of treatment period. There was only a slight 
reduction of phosphorylation AKT protein shown in Karpas299 cells after a 48 hours 
treatment with AUY922 with drug concentrations above 50 nM.  
In addition, we also examined one group of AKT downstream targets tightly associated with 
cell growth and apoptosis signalling. A member of the STAT protein family – STAT3 acts as 
a transcription activator, which is crucial to the pathogenesis of ALK+ ALCL. Western blotting 
was performed to compare Karpas299 cells with SUDHL-1 and BaF3 Cells (Fig. 20) during 
treatment with NVP-AUY922 in different drug concentrations and incubation times. Decrease 
in p-STAT3 was more obvious in SUDHL-1 cells than in Karps299 cells after a 24 hours 
treatment (Fig. 19A), but less than that in AKT and p-AKT proteins. However, after a 48 
hours treatment (Fig. 19B) of SUDHL-1 and BaF3-NPMAL cells with NVP-AUY922, the 
absence of STAT3 and p-STAT3 was detected with the dosage of 50 nM. In contrast, there 
was no significant change of the STAT3 and p-STAT3 in karpas299 cells. 
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Fig. 19: The Hsp90 inhibitor NVP-AUY922 inhibits expression of several oncoproteins or 
phosphorylation in SUDHL-1 but not in Karpas299 lymphoma cells. Cells were treated with 
the indicated concentration of AUY922 for 24 hours (A) and 48 hours (B). 
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Fig. 20: NVP-AUY922 inhibits expression of oncoproteins or phosphorylation in Baf3-
NPMALK only after 8 hours incubation. Cells were treated with the indicated concentration of 
AUY922 for 4 hours and 8 hours. 
 
4.3.4 A sensitive measure for Hsp90 inhibition of NPM-ALK+ ALCL using FLT-
uptake in vitro 
To determine whether Hsp90-NPM-ALK targeted treatment with AUY922 was assessable by 
measuring FLT and FDG-uptake, we examined the cellular tracer uptake of FLT and FDG in 
AUY922 treated BaF3-NPMALK, Karpas299, SUDHL-1 and SR-786 cells (Fig. 20). Cells 
were incubated with FLT or FDG for 45 min after a 48 hours treatment period and the activity 
was measured using a gamma-counter. As shown in Fig. 21D, Hsp90 inhibition led to a 
remarkable reduction of both FLT- and FDG-uptake in SUDHL-1 cells. However, the 
sensitivity of FLT was significantly higher showing a complete lack of FLT-uptake in the 
presence of 25 nM AUY922. In contrast, FDG-uptake was only reduced by 40% compared to 
the vehicle-treated control at the same dose level. These data suggest that FLT-uptake is 
more sensitive for determining effective NPM-ALK targeted treatment in vitro. 
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Fig. 21: FLT-uptake is more sensitive for determining effective NPM-ALK targeted treatment 
in vitro (A: BaF3-NPMALK cells, B: SR-786 cells, C: Karpas299 cells and D: SUDHL-1 cells). 
Cells were treated with the indicated concentration of AUY922 for 48 hours. The bars 
represent the mean ± SD of the mean from n=3 experiments. 
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4.4 Functional in vivo imaging of response to Hsp90 inhibition in SUDHL-
1 lymphoma by FLT-PET is superior to FDG-PET 
4.4.1 In vivo Hsp90 inhibition blocks the growth of the NPM-AKL lymphoma 
 
Once xenotransplants reached a size of approximately 0.3-0.8 cm³, mice (n=33) were treated 
with a single dose of NVP-AUY922 (25 mg/kg, i.p., daily). Tumor size was measured using a 
shifting calliper and the tumor volume was calculated using the formula: L*B*B/2.  
For SUDHL-1 lymphoma bearing mice, the control group (n=4, d0) received only a glucose 
solution. Treated mice showed a lower rate of tumor growth at d+7 (n=12, fold=1.3, SD=0.3, 
range 0.7-1.8-fold) than the control group (fold=2.9, SD=1.5, range 2.2-5.6-fold, Fig. 22A). 
After two weeks, the tumor volume of the control group increased from 0.4cm3 (n=4, SD=0.1, 
range 0.3-0.6) to 3.2cm3 (n=2, SD=1.0, range 2.46 cm3-3.88 cm3). In contrast, in the 
therapeutic group there was only a slight increase from 0.6cm3 (n=12, SD=0.2, range 0.2 
cm3-0.9 cm3) to 0.8cm3 (n=3, SD=0.2, range 0.5 cm3-1.0 cm3, Fig. 22A). 
As we showed in the in vitro studies, Karpas299 cells were detected with a partial resistance 
to the AUY922 treatment. Rather than SUDHL-1 cells, Karpas299 cells gave rise to xenograft 
tumors that were entirely resistant to targeted therapy with AUY922 (n=10, 25 mg/kg i.p. daily, 
mean 3.2-fold increase, SD=0.4, range 2.9-3.6). The karpas299 xenograft tumors grew at a 
rate similar to the control tumors (n=7, mean 5.2-fold increase, SD=1.5, range 2.8-7.6) (Fig. 
22B).  
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Fig. 22: NVP-AUY922 blocks the SUDHL-1 tumor growth. But Karpas299 lymphoma showed 
partially resistant to NVP-AUY922 treatment (Fig. A: SUDHL-1 lymphoma, Fig.B: Karpas299 
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lymphoma). The lymphoma bearing mice were treated intraperitoneally with 25 mg/kg 
AUY922 (Therapy) or only placebo (Control) daily. The bars represent the mean ± SD. 
 
4.4.2 FDG-PET imaging analysis shows inhibitory effect of Hsp90 inhibitor on 
the NPM-ALK lymphoma metabolism 
 
To investigate how SUDHL-1 lymphoma responded to the AUY922 treatment, FDG-PET was 
performed both before and after therapy at d-1, d+6 and d+14 in this study (Fig. 23A). Mean 
TBR (tumor to background ratio) of treated mice with a dose of 25 mg/kg reduced from 8.6 
(n=12, range 4.6-14.3, SD= 3.5) to 7.5(n=12, range 4.4-10.2, SD= 2.0), while the mean TBR 
of the untreated mice was increased from 5.7 (n= 4, range 2.3-8.1, SD= 2.5) to 13.2 (n=4, 
range 4.7-17.6, SD= 5.8) at d+6, but then reduced to 7.3 (n=3, range 5.6-9.0, SD= 1.7) at 
d+14. 
To analyse the therapeutic response of NPM-ALK lymphoma, the TBR of FDG-PET were 
also analysed statistically (Fig. 23B). FDG-PET analysis of control animals revealed a 
significant increase in FDG-uptake on day 5 (n=4, mean TBR 205.2%, range 195%-331.2%, 
SD=65%, p=0.03). In AUY922 treated animals, relative TBR of early FDG-PET did not show 
a significant reduction compared to the pre-treatment control (n=12, mean TBR 87%, 
SD=40.3%, range 31-161%; p=0.151, Fig. 23B). Interestingly, the mean TBR of FDG-uptake 
at later time points (day 15 to 21) decreased to 44% (n=3, SD=33.6%, range 23-85%) (data 
not shown). 
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Fig. 23A: AUY922 treatment reduces the FDG-tracer-uptake in SUDHL-1 lymphoma. The 
SUDHL-1 lymphoma bearing mice were treated intraperitoneally with 25 mg/kg AUY922 
(Therapy) or only placebo (Control) daily. Pre therapeutic FDG-PET was performed one day 
before therapy, post therapeutic FDG-PET were performed 6 days and 13 daysafter therapy. 
The bars represent the mean ± SD. 
 
Fig. 23B: Functional in vivo imaging of response to AUY922 inhibition in SUDHL-1 
lymphoma using FDG-PET and TBR on day 0, defined as 100% (“pre”), and change of TBR 
compared to pre-treatment values are shown for treated (“post”) and control animals. 
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Fig. 24: AUY922 treatment reduces the FLT-tracer-uptake in SUDHL-1 lymphoma. The 
SUDHL-1 lymphoma bearing mice were treated intraperitoneally with 50 mg/kg (Fig. A), 25 
mg/kg+10 mg/kg (Fig. B) or 25 mg/kg (Fig. C) AUY922 (Therapy) or only placebo (Control) 
daily. Pre therapeutic FLT-PET was performed one or two days before therapy, post 
therapeutic FLT-PET was performed 5 days and 14 days after therapy. The bars represent 
the mean ± SD 
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Fig. 25: Functional in vivo imaging of response to AUY922 inhibition in SUDHL-1 lymphoma 
using FLT-PET and TBR on day 0, defined as 100% (“pre”), and change of TBR compared to 
pre-treatment values are shown for treated (“post”) and control animals. 
 
 
 
 
 
76 
 
 
 
Fig. 26: No remarkable difference of FLT-tracer-uptake of karpas299 lymphoma was found in 
therapeutic group compare to control group. The SUDHL-1 lymphoma bearing mice were 
treated intraperitoneally with 25 mg/kg AUY922 (Therapy) or only placebo (Control) daily. Pre 
therapeutic FLT-PET was performed before therapy, post therapeutic FLT-PET was 
performed 2 days and 7 days after therapy. The bars represent the mean ± SD. 
 
 
4.4.3 FLT-PET imaging analysis shows the inhibitory effect of Hsp90 inhibitor 
on the proliferation of NPM-ALK lymphoma 
 
As a more tumor specific tracer compared to FDG, FLT was also investigated here. SUDHL-
1 and Katrpas299 bearing mice underwent FLT-PET both before and after therapy at d-1/d-2, 
d+1/d+5, and d+13, respectively. Figs. 24 to 25 showed representative TBR of different 
therapeutic groups. A marked decrease of SUDHL-1 FLT-uptake could be observed one day 
after therapy with 50 mg/kg AUY922 (n=5, pre therapeutic uptake: mean TBR= 3.7, range 
2.2-5.2, SD=1.2; post therapeutic uptake: mean TBR=2.5, rang 1.7-3.4, SD=0.5). In contrast, 
FLT-uptake remains high in the control mice (n=2, pre-therapeutic uptake: mean TBR= 1.7, 
range 1.6-1.8, SD=0.1; post-therapeutic uptake: mean TBR=2.1, rang 2.0-2.2, SD=0.1, Fig. 
24A).  However, these mice were dead after FLT-PET because of the toxic dose of 50 mg/kg. 
So we reduced the dose to 10 mg/kg as of d+2. A reduction of TBR of other two mice was 
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detected at d+1 from 2.1 to 1.7 (n=2, range 1.5-1.8, SD=0.1), while there was an increase of 
TBR in treated mice to 2.9 (n=2, range 2.7-3.1, SD=0.5) at d+14. There was no clear 
inhibition of tumor growth detected with 10 mg/kg treatment. The dose was increased to 25 
mg/kg in first week and then reduced to 10 mg/kg again to make sure that therapy was not 
toxic. The mean TBR was decreased from 2.9 (n=4, range 1.6-4.7, SD=1.6) at d-1 to 1.25 
(n=4, range 1.0-1.6, SD=0.3) at d+5, and then the dose of AUY922 was reduced to 10 mg/kg 
from d+5. No toxic effect was noticed until d+21. However, tumor volume began to increase 
and the mean TBR increased to 2.9 (n=4, range 1.9-3.0, SD=0.7, Fig. 24B) again after 14 
days treatment. After that a continuous therapy with 25 mg/kg was decided. The mean TBR 
was reduced from 3.7 (n=12, range 2.5-4.7, SD=0.7) to 1.6 (n=12, range 1.3-2.6, SD=0.4) at 
d+5 and further decreases were detected at d+13 ending at 1.0 (n=2, SD=0.01). In contrast, 
the TBR of all untreated mice increased from 1.7 (n=4, range, SD=0.5) to 3.6 (n=4, range 
2.8-4.1, SD=0.6) at d+5 and to 4.4 (n=3, range 3.6-5.7, SD=1.1, Fig. 24C) at d+13. To 
determine the predictive value of early functional imaging for response assessment, we 
performed FDG- and FLT-PET scans using a micro PET/CT system five days before or after 
initiation of AUY922 treatment. To do so, the change of TBR on day 5 was compared to pre-
treatment TBR, which was defined as 100%, was calculated (relative TBR). In contrast to 
FDG assessment, which shown no significant reduction of TBR from day 5, the relative mean 
TBR of FLT-uptake decreased significantly to 40% compared to baseline (n=12, SD=20.7%, 
range 32-67%, p=0.001) as early as 5 days after initiation of therapy (Fig. 25). The relative 
TBR of untreated controls increased to more than 200% during the same time period (n=4, 
mean TBR 207.8%, range 162.1%-302.4%, SD=61%, p=0.01). Later time points within the 
treatment group (day 15 to 21) did not show any further reduction in FLT-uptake (data not 
shown). The therapeutic response was also observed in AUY922 resistant Karpas299 
lymphoma bearing mice with a dose of 25 mg/kg (Fig. 26). The mean TBR of the control 
mice increased from 4.1 (n=7, range 2.9-5.3, SD=0.9) to 6.1(n=7, range 5.5-6.8, SD=0.5) at 
d+2, and then reduced to 4.2 (n=6, range 3.6-5.0, SD=0.6) at d+7. However, in the 
therapeutic group, the mean TBR increased from 4.7 (n=10, range 2.8-7.9, SD=1.7) to 5.9 
(n=10, range 3.6-9.7, SD=1.8) at d+2, and then went down to 4.0 (n=5, range 3.5-4.5, 
SD=0.4) at d+7. 
 
4.4.4 Histological analysis shows decreased proliferation and increased 
apoptosis induced by treatment with Hsp90 inhibitor in NPM-ALK lymphoma   
 
To correlate the PET findings with treatment effects of inhibitors on SUDHL-1 xenograft 
lymphomas, we stained fixed tumor sections using the proliferation marker Ki67 and using 
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cleaved caspase-3 to analyse apoptosis AUY922 treatment led to a significant increase in 
apoptosis as quantified by cleaved caspase-3 positive cells (Fig. 27C, n=5, mean 6.1%, 
SD=3.5%) compared to untreated mice (n=4, mean 1.6%, SD=1.1%; p=0.04). Moreover, the 
percentage of proliferating cells was substantially decreased by AUY922 as measured by 
Ki67staining with a mean of 15.3% (SD=0.8%) for the treated and 63.3% (SD=7%) for the 
control tumors (p=0.03).  
The PET findings of Karpas299 lymphomas were confirmed by immunohistochemistry as 
illustrated in Fig. 27B. No marked increase of apoptosis was detected after AUY922 
treatment (mean=0.86%, SD=0.52%) compared to control tumors (n=3, mean=1.0%, 
SD=0.5%). Moreover, AUY922 only led to a slight reduction of Ki67 staining in Karpas299 
tumors (therapeutic group: mean=47.1%, SD=3.1%, control group: mean= 57.7%, 
SD=5.61%). 
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Fig. 27: AUY922 treatment triggers a cell death (marker: caspase-3) and a reduction of 
proliferation (marker: Ki-67) in SUDHL-1 but not in karpas299 lymphoma in vivo (A: SUDHL-
1 lymphoma, B: karpas299 lymphoma, C: statistical analysis of SUDHL-1 lymphoma). The 
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lymphoma bearing mice were treated intraperitoneally with 25 mg/kg AUY922 (Therapy) or 
only placebo (Control) daily. 
 
4.5 Inhibition of mTOR blocks the proliferation of multiple ALK+ 
lymphoma cell lines   
4.5.1 Inhibition of mTOR activity affects the viability of ALK+ lymphoma cells  
 
To assess the biological effect of RAD001 on lymphoma cell survival, we performed MTT 
assays on SUDHL-1 and Karpas299 cells, incubated with increasing concentrations of the 
drug for 24 hours, 48 hours and 72 hoours (Fig.28A-F). All the cell lines showed a dose-
dependent decrease in cell viability. Both Karpas299 cells and SUDHL-1 cells were sensitive 
to RAD001. To investigate time dependent effect of RAD001 treatment, SUDHL-1 and 
Karoas299 cell lines were treated for 24 hours, 48 hours and 72 hours. There was only slight 
effect on viability after 24 hours of an incubation period in both cell lines (Fig. 28A and 28D). 
Inhibition rates of SUDHL-1 cells were 59% after the 48 hours incubation and 63% after the 
72 hours incubation, respectively (RAD001 concentration: 1 nM) (Fig. 28E and 28F). The 
IC50 of SUDHL-1 cells was found after a 48 hours incubation with drug dose of 1 nM. Under 
treatment with 1 nM RAD001, the viability of Karpas299 cells reduced from 100% of controls 
to 42% of treated cells (48hours) and to 32% (72hours) (Figs. 28A and 28B). As shown in 
Figs. 28A-F, although the lower concentrations (0.1 nM) of RAD001 had almost no effect on 
cell proliferations, RAD001 significantly inhibited proliferation of both cells in a dose-
dependent manner. Karpas299 cells viability was from 97% (0.1 nM) to 36% (1000 nM) as 
early as 24 hours, respectively (Fig. 28A). Additionally, the dramatically inhibition of 
Karpas299 cells viability was also found after 48 hours and 72 hours incubation with RAD001 
(Figs. 28B and 28C). These findings were also confirmed by the observed cell cycle and 
apoptosis assay. 
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Fig. 28: mTOR inhibitor RAD001 (everolimus) inhibits the cell viability in the time and dose 
dependent Manner in karpas299 and SUDHL-1 cells. Cells were treated with the indicated 
concentration of RAD001 for 24 hours, 48 hours and 72 hours. The bars represent the mean 
± SD of the mean from n=3 experiments. 
 
 
 
4.5.2 Inhibition of mTOR activity triggers the cell cycle arrest but not apoptosis 
in ALK+ lymphoma cells in vitro    
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We have studied the effect of RAD001 treatment for 24 hours and 48 hours on the course of 
cell cycle of SUDHL-1 and Karpas299 lymphoma cells. The cell cycle was detected using PI-
staining FACS assay. RAD001 induced marked accumulation in the G1 phase in both cell 
lines. The results showed that RAD001 arrested SUDHL-1 lymphoma cells in the original the 
G1 (from 43% in the control to 53% at 1 nM), while a reduction of cells in the S phase was 
observed (from 22% in control to 14% at 1 nM) as early as 24 hours (Fig.29C). At 48 hours, 
cells in the S phase (from 19% in control to 10% at 1 nM) had traversed to the G1 phase 
(from 44% in control to 60% at 1 nM). There was no change in the SubG1 phase, indicating 
apoptosis (Fig. 29D). Upon treatment with RAD001, Karpas299 cells presented an increase 
in the percentage of cells accumulating in the G1 phase (from 38% in control reaching a 
peak value of 55% at 1 nM dosage), while the cells of the S phase decreased (from 27% in 
control reaching a value of 16% at 1 nM dosage) as early as 24 hours (Fig. 29A). After 48 
hours treatment with RAD001, cells traversed to the G1 phase (from 46% in the control 
reaching a peak value of 54% at the 1 nM dosage) and the S phase (from 23% in control 
reaching to 17% at 1 nM dosage). There was no significant change in either SubG1 or G2 
phase (Fig. 29B). 
The Annexin V-FACS was also performed to studied the effect of RAD001 (everolimus) 
treatment on BaF3-NPMALK, JB-6 Karpas299, SUDHL-1, SUP-M2 and SR-786 lymphoma 
cells. The results showed that RAD001 (everolimus) caused no remarkable cell death in all 
these lymphoma cells (Fig. 30 and 31). Furthermore, SUP-M2 and SR-789 lymphoma cells 
are resistant to RAD001 treatment as detecting with Annexin V and PI-FACS (Fig. 31). 
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Fig. 29: mTOR inhibitor RAD001 (everolimus) induces the cell cycle arrest (G1-phase) but 
no apoptosis in ALCL lymphoma cells. Cells were treated with the indicated concentration of 
RAD001 (everolimus) for 24 hours and 48 hours. The bars represent the mean ± SD of the 
mean from n=3 experiments. 
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Fig. 30: mTOR inhibitor RAD001 (everolimus) treatment did not cause the apoptosis in ALCL 
cells (A: BaF3-NPMAL cells, B: JB-6 cells, C: Karpas299 cells, D: SUDHL-1 cells) as 
determined using Annexin V-FACS. Cells were treated with the indicated concentration of 
RAD001 (everolimus) for 48hours. The bars represent the mean ± SD of the mean from n=3 
experiments. 
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Fig. 31: SUP-M2 and SR-789 cells shown resistant to RAD001 (everolimus) treatment as 
determined using Annexin V and PI-FACS. Cells were treated with the indicated 
concentration of RAD001 (everolimus) for 48hours. The bars represent the mean ± SD of the 
mean from n=3 experiments. 
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4.5.3 Down-regulation of several oncogenic proteins during exposure of human 
lymphoma cells to mTOR inhibitor  
 
To investigate effects of RAD001 treatment on mTOR signalling, we used Western blotting to 
analyse levels of the phosphorylated forms of p70S6K and non-phosphorylated forms of 
p70S6K after 24 hours and 48 hours exposure of SUDHL-1 and Karpas299 cells to various 
doses of RAD001. In these two cell lines, levels of the phosphorylated forms of p70S6K were 
reduced up on increase of concentration of RAD001. However, the effects of RAD001 on 
non-phosphorylated form of protein levels in these tow cell lines were not found with 
increasing RAD001 dose (Fig. 32A and Fig. 32B).  
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Fig. 32: mTOR inhibitor RAD001 (everolimus) inhibits the phosphorylation of p70 S6K in both 
SUDHL-1 and Karpas299 cells on a dosage dependent manner. Cells were treated with the 
indicated concentration of RAD001 (everolimus) for 24 hours (A) and 48 hours (B). 
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4.5.4 A sensitive measure for mTOR inhibition of NPM-ALK+ ALCL using FLT-
uptake in vitro 
To determine whether mTOR targeted treatment with RAD001 (Everolimus) was assessable 
by measuring FLT and FDG-uptake, we examined the cellular tracer uptake of FLT and FDG 
in RAD001 (Everolimus) treated cells. BaF3-NPMALK, JB-6, Karpas299, SUDHL-1, SUP-M2 
and SR-786 cells were incubated with FLT or FDG for 45 min after a 48hours treatment 
period and the activity was measured using a gamma-counter. As shown in Fig. 35, RAD001 
(Everolimus) treatment did not lead to a remarkable reduction of both FLT- and FDG-uptake 
in most of these cell lines.  
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Fig. 33: In comparison with NVP-AUY922, RAD001 treatment does not cause the  
remarkable reduction of tracer-uptake in vitro. (A: BaF3-NPMALK cells, B: JB-6 cells, C: 
Karpas299 cells, D: SUDHL-1 cells and E: SR-786 cells). Cells were treated with the 
indicated concentration of AUY922 for 48 hours. The bars represent the mean ± SD of the 
mean from n=3 experiments. 
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4.6 Functional imaging of mTOR inhibition in ALCL xenografts by FLT-
PET is superior to FDG-PET 
4.6.1 In vivo mTOR inhibition blocks the growth of the NPM-ALK lymphoma  
 
In SUDHL-1 lymphoma bearing mice, control group received a glucose solution only. The 
treated mice showed a lower rate of tumor growth at d+7 (n=12, fold=1.0, SD=0.6, range 0.3-
2.4-fold) than the control mice (fold=2.6, SD=1.1, range 2.0-4.9-fold, Fig. 34a). After two 
weeks therapeutic period, the tumor volume of the control group increased from 0.3cm3 (n=7, 
SD=0.07, range 0.3-0.4) to 1.2cm3 (n=4, SD=0.4, range 0.7-2.7 cm3). In contrast, the tumor 
volume of the therapeutic mice reduced from 0.4(n=12, SD=0.2, range 0.3-0.8 cm3) to 
0.4cm3 (n=6, SD=0.2, range 0.1-0.5 cm3). 
As shown in cellular studies, Karpas299 cells are also sensitive to RAD001 treatment in vitro. 
The tumor volume of therapeutic group increased only slightly from 0.5 cm³ (n=7, range 0.5-
0.7 cm³, SD=0.1) to 0.8 cm³ (n=7, range 0.5-1.6 cm³, SD=0.4) at d+7. In contrast, the tumor 
volume of control mice was increased from 0.6 cm³ (n=7, range 0.3-0.9 cm³, SD=0.2) to 2.6 
cm³ (n=7, range 1.3-3.6 cm³, SD=0.9) at d+7 (Fig. 34B) 
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Fig. 34: RAD001 (everolimus) blocks the SUDHL-1 and Karpas299 tumor growth (A: 
SUDHL-1 lymphoma, B: Karpas299 lymphoma). The lymphoma bearing mice were treated 
oral with 5 mg/kg RAD001 (everolimus) (RAD001) or only placebo (Control) daily. The bars 
represent the mean ± SD. 
 
4.6.2 FDG-PET imaging analysis shows inhibitory effect of mTOR inhibitor on 
the NPM-ALK lymphoma metabolism   
 
To confirm the predictive value of FLT-PET imaging for early response evaluation 
using targeted agents, we treated mice bearing SUDHL-1 xenograft tumors with another 
compound, the mTOR inhibitor RAD001, and evaluated the efficacy of FDG- and FLT-PET 
monitoring. NPM-ALK-positive cells have previously been shown to undergo cell cycle arrest 
and apoptosis upon mTOR inhibition (106). Again, treatment was started when mice had 
measurable xenograft tumors. To investigate SUDHL-1 lymphoma in response to RAD001 
treatment, FDG-PET was performed both before and after therapy at d-1 and d+7 (Fig. 35). 
The mean TBR of the treated mice with a dose of 5 mg/kg was reduced from 8.9 (at d-1: n=9, 
range 3.4-11.8, SD= 3.6) to 7.1 (at d+7: n=9, range 3.7-8.2, SD= 1.7). The mean TBR of the 
untreated mice had almost no change (at d-1: n= 7, mean=9.3, range 2.6-15.9, SD= 4.2; at 
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d+7: n=4, mean=8.9, range 4.2-12.5, SD= 3.3). Furthermore, the statistical analysis using the 
Graphpad system was also done here. As depicted in Fig. 36, tumor growth was completely 
inhibited by RAD001 (n=12), whereas the size of control tumors steadily increased over time 
(n=7, mean 5.6-fold, SD=1.6). By using FDG-PET only a marginal, non-significant reduction 
of tracer uptake could be observed 5 days after therapy initiation compared to pre-treatment 
values (p=0.6, Fig. 36). Although RAD001 treated tumors revealed less FDG-uptake 
compared to control tumors, this difference did not reach statistical significance. 
 
4.6.3 FLT-PET imaging analysis shows inhibitory effect of mTOR inhibitor on 
the proliferation of NPM-ALK lymphoma  
 
As a more tumor specific tracer, FLT-uptake in xenograft tumors was investigated during 
RAD001 treatment. SUDHL-1 and Katrpas299 bearing mice were scanned with FLT-PET 
both before and after therapy at d-2 and d+7, respectively. Figs. 37a and 37b show 
representative TBRs of different therapeutic groups. A remarkable decrease of SUDHL-1 
FLT-uptake could be detected two weeks after therapy with 5 mg/kg RAD001 (n=6, pre-
therapeutic uptake: mean TBR= 2.9, range 2.3-4.7, SD=0.7; post-therapeutic uptake: mean 
TBR=1.3, range 1.0-1.7, SD=0.2). In contrast, the FLT-uptake remained change in the 
control mice (n=3, pre-therapeutic uptake: mean TBR= 2.6, range 1.9-2.7, SD=0.5; post-
therapeutic uptake: mean TBR=2.6, rang 2.7-3.6, SD=0.7) until d+14. Only a slight decrease 
of FLT-uptake of control mice was detected at d+7. The mean TBR of the therapeutic mice 
was 2.4 (at d+7: n=6, range 1.9-2.8, SD=0.6) and the TBR increased slightly to 2.9 (at d+7: 
n=3, range 2.1-3.4 SD=0.1) in controls (Fig. 37a). The therapeutic response was observed in 
RAD001 sensitive Karpas299 lymphoma bearing mice under dose of 5 mg/kg. Fig. 37b 
showed that the mean TBR of therapeutic group reduced from 3.5 (n=8, range 2.6-4.1, 
SD=0.6) to 5.8 (n=4, range 4.2-6.8, SD=1.1) at d+2, and then increase slightly to 5.0 (n=4, 
range 3.6-6.0, SD=1.0) at d+7. In controls, the mean TBR was increased from 4.3 (n=7, 
range 2.3-6.3, SD=1.4) to 5.4 (n=3, range 4.9-6.1, SD=0.6) at d+2, but then reduced at d+7 
(n=3, mean=5.2, range 4.8-5.8, SD=0.5). The statistical analysis of TBR of FLT-PET show 
that . In contrast of the non-significant reduction of FDG-PET, FLT-PET was able to 
significantly discriminate between control and treatment group (Fig.38). In addition, we found 
a modest, but statistically significant reduction of FLT-uptake before and after initiation of 
RAD001 application (p=0.01). 
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Fig. 35: RAD001 (everolimus) treatment reduces the FDG-tracer-uptake in SUDHL-1 
lymphoma. The SUDHL-1 lymphoma bearing mice were treated oral with 5 mg/kg RAD001 
(everolimus) (RAD001) or only placebo (Control) daily. Pre therapeutic FDG-PET was 
performed one day before therapy, post therapeutic FDG-PET were performed 6 days after 
therapy. The bars represent the mean ± SD. 
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Fig. 36: Functional in vivo imaging of response to RAD001 inhibition in SUDHL-1 lymphoma 
using FDG-PET and TBR on day 0, defined as 100% (“pre”), and change of TBR compared 
to pre-treatment values are shown for treated (“post”) and control animals. 
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Fig. 37: RAD001 (everolimus) treatment reduces the FLT-tracer-uptake in both SUDHL-1 
(A)and Karpas299 (B) lymphoma. The lymphoma bearing mice were treated oral with 5 
mg/kg RAD001 (everolimus) (RAD001) or only placebo (Control) daily. Pre therapeutic FDG-
PET was performed two days before therapy, post therapeutic FLT-PET were performed 2 
and 6 or 7 days after therapy. The bars represent the mean ± SD. 
 
Fig. 38: Functional in vivo imaging of response to RAD001 inhibition in SUDHL-1 lymphoma 
using FLT-PET and TBR on day 0, defined as 100% (“pre”), and change of TBR compared to 
pre-treatment values are shown for treated (“post”) and control animals. 
 
4.6.4 Histological analysis shows decreased proliferation and increased 
apoptosis induced by treatment with mTOR inhibitor in NMP-ALK lymphoma  
 
To confirm these data on the histological level, we analyzed the tumor tissue for cleaved 
capase-3 and Ki67 expression (Fig. 39). Treated tumors harboured more cleaved caspase-3-
positive cells compared to control tumors (6.2% vs. 2.2%, p=0.04). Notably, exposure to 
RAD001 dramatically decreased the percentage of Ki67-positive cells from57.1% to 20.3% 
(p<0.0001). These results were substantiated by further in vitro studies. Using MTT assays, 
we observed a reduction of cell growth to approximately 20% after incubation with 1 nM 
RAD001 for 48 hours compared to untreated cells (Fig. 28). At the same dose level, PI 
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staining revealed a 50% decrease of cells in S phase and a marked increase of cells in 
G0/G1 phase, whereas the sub-G1 fraction was low and unaffected by mTOR inhibition (Fig. 
29). 
In vitro efficacy could also be demonstrated by immunoblot analysis showing an abrogation 
of p70S6 kinase phosphorylation at a dose as low as 1 nM (Fig. 32). Thus, functional 
imaging with FLT-PET rather than FDG-PET has a predictive value for response to mTOR 
inhibition 
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Fig. 39: RAD001 (everolimus) treatment triggers a cell death (marker: caspase-3) and a 
reduction of proliferation (marker: Ki-67) in both SUDHL-1 and in karpas299 lymphoma in 
vivo (A: SUDHL-1 lymphoma, B: karpas299 lymphoma, C: statistical analysis). The 
lymphoma bearing mice were treated oral with 5 mg/kg AUY922 (Therapy) or only placebo 
(Control) daily. 
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4.7 Validating the predictive value of FLT-PET imaging for therapy 
monitoring in vivo and in vitro 
 
Depending on our in vitro study, Karpas299 ALCL cells were not responsive to HSP90 
inhibition by AUY922 treatment but sensitive to mTOR. After a treatment period of 48 hours 
cell cycle distribution was analyzed by PI staining. In vitro study shows that AUY922 had 
virtually no effect on cell cycle distribution. However, Karpas299 were sensitive to RAd001 
treatment resulting in an approximately 50% reduction of cells in S phase compared to 
control cells (Fig. 29A and B). In order to support the distinct biological effects of HSP90 and 
mTOR inhibition, we analyzed the biochemical effects of both inhibitors on oncogenic signal 
transduction by immunoblotting (Fig. 20 and Fig. 32). Consistent with the PI staining results 
and in sharp contrast to SUHDL-1 cells, HSP90 inhibition did not downregulate ALK or 
phospho-ALK protein levels. Moreover, the downstream targets phospho-Akt and Akt levels 
as well as phospho-STAT3 and STAT3 levels were virtually unchanged upon AUY922 
treatment up to concentrations of 50 nM and 100 nM, respectively (Fig. 20). Importantly, 
incubation of Karpas299 cells with RAD001 abrogated the phosphorylation of the mTOR 
downstream target p70S6 kinase at the same dose level (1 nM) compared to SUDHL-1 cells 
(Fig. 32).  
 
Then, to evaluate the selectivity of FLT-PET to predict response to pathway targeted therapy, 
we used a different NPM-ALK expressing lymphoma cell line, Karpas299. Differently from 
SUDHL-1 ALCL cells, Karpas299 ALCL cells gave rise to xenograft tumors that were entirely 
resistant to targeted therapy with AUY922 (mean 3.2-fold increase, SD=0.4, range 2.9-3.6), 
resulting in a similar growth rate as control tumors (n=7, mean 5.2-fold increase, SD=1.5, 
range 2.8-7.6) (Fig. 40). In contrast, RAD001 treatment (mean 1.0-fold increase, SD=0.2, 
range 0.9-1.2) abrogated further Karpas299 tumor growth. FLT-PET scans were performed 
before and two days after initiation of therapy and relative TBRs of each treatment group 
were calculated. As expected, relative TBR of FLT-uptake of both control and AUY922 
treated animals did not differ from each other (p=0.42, Fig. 41) and increased to a mean of 
154% (range 107-202%; SD=35.5%) and 149% (range 46% to 175%, SD=47.2%), 
respectively. Most importantly, FLT-PET imaging showed a significant decrease of the 
relative TBR of RAD001 treated Karpas299 tumors compared to the respective control 
(mean 92%, SD=37%, range 44-163%, p=0.001), again correctly predicting tumor growth 
kinetics of this treatment. Thus, FLT-PET seems to be suitable to discriminate between 
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response and resistance to targeted therapy at a very early time point. The PET findings 
were confirmed by immunohistochemistry. Compared to vehicle, RAD001 induced a 
significant increase of apoptosis as detected by caspase-3 staining (Fig. 42A, p=0.02). In 
contrast, no significant induction of apoptosis was detected after AUY922 treatment 
compared to control tumors (p=0.5). In addition, the percentage of Ki67 positive cells was 
significantly reduced after treatment with everolimus (Fig. 42B) in contrast to control tumors 
(p=0.02), indicating a strong induction of cell cycle arrest. AUY922 also led to a slight 
reduction of Ki67 staining, however not to the level of statistical significance (p=0.1). Taken 
together, these data strongly support superiority of FLT-PET imaging for response prediction 
in vivo, thus allowing an early distinction between sensitive and refractory disease. Our 
studies thus provide strong evidence that FLT-PET appears to be highly suitable to predict 
early response to targeted therapy in vivo.  
 
 
 
Fig. 40: RAD001 but not AUY922 blocks the Karpas299 tumor growth. The karpas299 
lymphoma bearing mice were treated intraperitoneally with 25 mg/kg AUY922 or treated oral 
with 5 mg/kg RAD001 or placebo (Control) daily. The bars represent the mean ± SD. 
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Fig. 41: Functional in vivo imaging of response to AUY922 or RAD001 inhibition in 
Karpas299 lymphoma using FLT-PET, was performed before (day 0) and two days after 
initiation of therapy. Left panel: TBR was calculated and served as an indicator of tracer 
uptake. TBR on day 0 was defined as 100%. Change of TBR compared to pre-treatment 
value is shown for each group. Right panel: representative PET scans showing change of 
tumor tracer uptake (arrows).The bars represent the mean ± SD. 
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Fig. 42: RAD001 but not AUY922 causes the significant cell death (marker: caspase-3, A) 
and reduction of proliferation (marker: Ki-67, B) of Karpas299 lymphoma in vivo. The 
karpas299 lymphoma bearing mice were treated intraperitoneally with 25 mg/kg AUY922 or 
treated oral with 5 mg/kg RAD001 or placebo (Control) daily. The bars represent the mean ± 
SD. 
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5 Discussion 
 
Ongoing progress in the understanding of lymphoma pathogenesis has led to the large-scale 
development of a multitude of pathway targeting drugs (107-109). To optimize design and 
interpretation of clinical trials using novel compounds it will be crucial to identify biomarkers 
of sensitivity and response. Once identified, these markers will also accelerate validation of 
effective drug combinations in the preclinical setting.  
Though pharmacodynamic biomarkers assess target inhibition and pathway downregulation, 
this does not necessarily equate with clinical benefit (110). In addition, many biomarker 
assays have been neither standardized nor validated (111). Thus, it is unlikely that in the 
majority of patients with advanced lymphoma the mere presence of a biomarker, a genetic 
profile, or an activated pathway will suffice to predict response to targeted therapy early in 
the course of treatment.  
For example, the therapy targets PI3K/AKT/mTOR pathway. The PI3Ks are a family of lipid 
kinases that share the primary biochemical function to phosphorylate the 3-hydroxyl group of 
phosphoinositides (112).Three classes (I-III) of PI3K are described that vary in structure and 
substrate preference. The heterodimers that make up class I PI3Ks consist of a regulatory 
and a catalytic subunit. In the class IA group, these are p85 and p110 (α, β and δ), 
respectively, whereas the class IB PI3K consists of p101 and p110γ (113). Class II PI3Ks are 
monomeric catalytic isoforms, and the sole class III member is Vps34. Meanwhile, upstream 
receptor tyrosine kinases (RTKs) that feed into the PI3K pathway include members of the 
human epidermal growth factor receptor family (EGFR and HER2), platelet derived growth 
factor receptor, and the insulin and insulin-like growth factor 1 (IGF-1) receptors. 
Engagement of a growth factor with its RTK is the typical initiating event for activation of 
class IA PI3Ks, where RTK stimulation leads to an interaction with p85 in the tyrosine kinase 
domain. Furthermore, AKT, a serine/threonine kinase, is the central mediator of the PI3K 
pathway with multiple downstream effectors that influence key cellular processes (see figure 
1). AKT stimulates protein synthesis and cell growth by activating mTOR (as part of the 
mTOR-raptor or mTORC1 complex) through effects on the intermediary tuberous sclerosis 
(TSC) 1/2 complex. It influences cellular proliferation by inactivating cell cycle inhibitors (p27 
and p21) and promoting cell cycle proteins (c-Myc and cyclin D1) (114). AKT mediated 
inhibition of pro-apoptotic genes (BAD and BIM) and degradation of the tumor suppressor 
protein p53 limits programmed cell death and enhances cell survival (115). PI3K also 
features in cellular metabolism and insulin signaling through actions on GSK3 (116). 
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Heretofore, a variety of PI3K/Akt/mTOR pathways has emerged. As part of the mTORC1 
complex, mTOR stimulates cell growth and protein synthesis through effects on mRNA 
translation and ribosome biogenesis (117). Rapamycin is a macrolide antibiotic originally 
derived from Streptomyces hygroscopicus found in the soil on the island of Rapa Nui. 
Rapamycin (and its analogues, also known as rapalogs) acts by binding to the FKBP12 
binding protein, which in turn interacts with the mTORC1 complex, inhibiting downstream 
signaling (118). The other rapalogs, synthetic derivatives of rapamycin with improved 
properties, are temsirolimus, everolimus (RAD001) and ridaforolimus (AP23573), formerly 
known as deforolimus. 
At the same time, a series of compounds are currently passing through the early phases of 
clinical development. ‘Pure’ PI3K inhibitors target only p110; both pan-p110 inhibitors and 
isoform-specific inhibitors exist. As the catalytic domains of the p110 subunits and mTOR are 
structurally similar, dual inhibitors of both PI3K and mTOR and are also emerging. SF1126 
has shown significant anti-tumor effects in xenograft models of solid tumors including 
glioblastoma, breast and prostate cancer, and potent anti-angiogenic activity has also been 
observed, felt partly to be related to a reduction in HIF-1α levels (48).Two other dual 
inhibitors are under investigation by Novartis – NVP-BEZ235 and NVP- BGT226 – (there is 
currently no presented or published data relating to NVP-BGT226, but we have determined 
the anti-tumor effect of BGT226 in our study). NVP-BEZ235 is an orally available product 
belonging to the class of imidazoquinolines (119). Preclinical studies demonstrated anti-
proliferative activity against a wide range of cancer cell lines, including HER2-overexpressing 
breast cancer models of trastuzumab and lapatinib resistance (120, 121). NVP-BGT226 as a 
PI3K/mTOR also shows anti-tumor effect in our ALCL models as described before. The 
majority of compounds described as pure PI3K inhibitors are pan-p110 inhibitors. However, 
at least one isoform-specific inhibitor (CAL-101) has had preliminary results presented. NVP-
BKM120 is one such agent, and preclinical data showed anti-tumor activity in xenograft 
models of human cancer both with and without PI3K/PTEN mutations (122). 
Direct inhibition of the serine/threonine kinase AKT provides another avenue to 
pharmacologically regulate activity of the PI3K pathway. The two strategies being explored 
involve agents that compete for the ATP-binding site (ATP mimetics) and those that act away 
from this catalytic site (allosteric inhibitors) (123). Perifosine is an allosteric inhibitor that 
targets the PH domain of AKT, thereby preventing its translocation to the plasma membrane 
required for activation (124). MK-2206 is another allosteric Akt inhibitor. In preclinical studies, 
synergism has been demonstrated when MK-2206 has been used in combination with other 
targeted therapies (erlotinib, lapatinib) or a host of cytotoxic agents (125). Preliminary results 
of a phase I study in solid tumors have been presented (126). GSK690693 is a potent ATP-
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competitive AKT inhibitor that also inhibits the phosphorylation of the downstream target 
GSK3 in cells. It is currently in clinical development as an intravenous agent for use in 
patients with solid tumors or hematological malignancies (127). 
Biomarker studies are becoming increasingly incorporated into early phase clinical trials. This 
is largely true for the phase I trials of PI3K pathway inhibitors described above where various 
predictive and pharmacodynamic (PD) biomarkers have been explored. PD biomarkers are 
markers of drug effect that assess for target inhibition and pathway downregulation. They 
necessitate assessment prior to and following an intervention to detect a change from 
baseline; a correlation with clinical activity is not implied but is desirable (122). At present, an 
important concern is that many biomarker assays have been neither standardized nor 
validated. They add to the cost of the trial and may involve invasive procedures that carry a 
degree of risk to the patient. Markman et al. took the evaluation of PTEN status as a prime 
example. Because functional PTEN loss can occur through a variety of mechanisms, 
detection of PTEN protein expression by immunohistochemistry (IHC) on tumor samples is 
the preferred method. However, the antibodies used to stain samples are not uniform 
between laboratories, nor has a definitive cut-off been defined below which PTEN is 
considered to be lost. Further, the adequacy of archival compared to fresh tissue has not 
been delineated. And given that tumor samples are often small and difficult to obtain, how 
biomarker studies ought to be prioritized is not clear (122). 
Functional in vivo imaging could therefore be useful to assess and predict response to a 
specific treatment very early upon targeted treatment initiation using different Inhibitors, at a 
time point, when conventional imaging using computed tomography or magnetic response 
techniques cannot be expected to detect either response or resistance. 
Our studies used the molecularly defined lymphoma entity ALCL, characterized by ALK-
dependent pathway activation, to functionally evaluate the standard PET tracer FDG and the 
thymidine analogue FLT as early response markers. Constitutive ALK activation is a 
characteristic of NPM-ALK positive lymphoma and results in the activation of PI3K-AKT-
mTOR and JAK-STAT signalling. Both are critical survival and proliferation pathways and 
have been proposed as pharmacologic targets for malignant diseases including lymphoma 
(17, 18, 128, 129). Based on the defined oncogene and subsequently deregulated signal 
transduction, which can be blocked by specific inhibitors, we felt that these lymphoma cells 
are most suitable for a translational approach comprising both in vitro and in vivo assays. 
BGT226 is a pan PI3K/mTOR inhibitor that is also under investigation by Novartis. We have 
shown in our work that BGT226 has an anti-tumor activity in the xenograft ALK+ ALCL 
models. Moreover, it arrests cell in SubG1-G1 phase and inhibits the Akt phosphorylation as 
104 
 
early as 16 hours after start of incubation. Hsp90 has been identified as an attractive target 
for anticancer therapy, since its inhibition effectively induced apoptosis in ALK+ ALCL cell 
lines through the accelerated degradation of NPM-ALK and other proteins (130, 131). The 
Hsp90 inhibitor, NVP-AUY922, triggers cell apoptosis and cause cell cycle arrest in G1 
phase. Several oncoproteins are down-regulated from AUY922 therapy after 48 hours. 
Furthermore, AUY922 strongly blocks the ALCL tumor growth in vivo. RAd001 is an 
approved, well-tolerated mTOR inhibitor that has also shown efficacy in numerous tumors 
including lymphatic malignancies (132). It arrests ALK+ ALCL cells in G1 phase, but we have 
not found the cell apoptosis in vitro from RAD001 treatment. Phosphorylation of mTOR 
downstream receptor p70 S6K is totally inhibited from 48 hours RAD001 treatment at 1 nM. 
We also show that FLT-uptake by lymphoma cells during inhibition of NPM-ALK or NPM-ALK 
downstream pathways closely reflected antiproliferative response. Moreover, there is a 
strong correlation between in vivo and in vitro results including western blot analyses 
assessing the activation of NPM-ALK and NPM-ALK-dependent pathways. Most importantly, 
early changes of TBR of FLT-, but not FDG-PET, preceded change of tumor volume thus 
allowing distinction between sensitive and resistant cell lines and prediction of therapy 
response.  
FDG-PET after completion of therapy is the non-invasive modality of choice for response 
classifications of aggressive lymphomas (133). Regarding interim FDG-PET during 
lymphoma treatment recent clinical studies investigating its predicitive value have clearly 
attenuated the validity in this scenario (134, 135). Moreover, FDG-PET did not predict tumor 
response during mTOR inhibition both in patients with advanced solid tumors and murine 
xenograft models (136) emphasizing the need for new surrogate markers reflecting early 
antiproliferative rather than metabolic response. FLT has been shown to accumulate in a 
variety of tumor entities due to intracellular trapping upon phosphorylation by the S phase 
enzyme thymidine kinase 1 (TK1) (93, 96, 99, 100, 137, 138). The correlation between TK1 
activity and cellular uptake renders FLT an excellent surrogate marker of proliferation (139, 
140).   
Since, the lack of FDG to reflect anti-tumor response early after initiation of Hsp90 or mTOR-
targeted therapy is in accordance with results from other preclinical models for breast cancer 
(141, 142), ovarian cancer (143) and pancreatic cancer (136). It is likely that an influx of 
inflammatory cells which can be observed already 48 hours after mTOR inhibition (144) 
contributes to higher FDG-uptake in vivo. While FDG-uptake of inflammatory cells is similar 
or may even exceed that of tumor cells, transient increase in stromal reaction may result in 
overestimation of viable tumor cells (145). The observed dispersion of FDG-uptake might in 
addition be attributed to a variable degree of inhibition of glycolysis as a consequence of 
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disruption of the AKT-pathway resulting in altered FDG-uptake (136, 146). On the contrary, 
FLT-uptake has been proven as a valid imaging biomarker for abrogation of the PI3K-AKT-
mTOR pathway in solid tumors (143, 147). Inhibition of the NPM-ALK downstream pathway 
is known to induce cell cycle arrest in G1 phase due to increase of p27 and decrease of 
cyclin D1 expression, a state resulting in low TK1 activity (148). Being a substrate of TK1, 
FLT thus appears as the ideal surrogate marker for inhibition of this pathway. Consistently, 
we observed a significant reduction of FLT-uptake on day 5 after commencement of both 
Hsp90 and mTOR inhibition as measured by TBR of FLT-PET. Effective targeting was 
validated by documentation of tumor growth and immunostaining of explanted lymphomas, 
which revealed both a significant reduction of the proliferation and, to a lesser extent, 
increase of the apoptosis.  
However,  other thymidine analogs such as 2’-[18F]-fluoro-beta-D-arabinofuranosyl-uracil 
(FMAU) or 1-(2’-deoxy-2’-fluoro-beta-D-arabino-furanosy)-5-[76Br]-bromouracil (BFU) are 
incorporated in to DNA up to 97% of total cell activity and are therefore potentially more 
suitable proliferation markers (149). Yet such radiopyrimidines have not yet been studied in 
vivo. It remains to be determined which radionucleoside is most appropriate for in vivo-
assessment of tumor proliferation. In tumors with low TK1 expression levels or low 
proliferation fraction (e.g., low-grade lymphomas), [18F]-FLT may be less useful for 
assessment of therapy response. Recent publications indicate that the metabolism of [18F]-
FLT is complex, especially in a post-therapy situation (150). Perumal et al. reported that 
[18F]-FLT-uptake is related to the expression of equilibrative nucleoside transporters (ENT) 
(151). Kenny has found a heterogenous pattern of FLT-uptake in primary tumors and 
metastases from breast cancer (152). Heterogeneity of tumors potentially explains the 
relatively high variability of [18F]-FLT-uptake found in experimental tumors. A recent study by 
Muzi et al. indicates that metabolites of [18F]-FLT, especially [18F]-FLT-glucuronide, may 
count for up to 30% of the blood activity and can therefore contribute to tumoral [18F]-FLT-
uptake (153). Furthermore, in a therapy related treatment with inhibitors of thymidine 
monophosphate de novo synthesis (5-fluorouracil (5-FU), methotrexate), a 7-to10-fold 
increase of [18F]-FLT-uptake in esophageal carcinoma cells was observed. The authors 
speculated that this finding was caused by activation of the thymidylate salvage pathway and 
an increase in TK1activity (102). In agreement with this in vivo study, Barthel et al. have 
found an increasing in TK1 protein levels 48h after 5-FU treatment of fibrosarcoma bearing 
mice (97). However, treatment leads to a reduction of proliferation fraction and decreased 
[18F]-FLT-uptake. This finding may be explained by a decrease in cytoplasmic ATP levels 
since ATP is an important cofactor of TK1 activity. In the presence of ATP, TK1 forms a 
tetramer which is 20-fold more effective compared to the dimmer regarding phosphorylation 
of [18F]-FLT. Changes in ATP levels have therefore a major impact on cellular uptake of 
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[18F]-FLT. In the latter study, a decrease of [18F]-FLT-uptake was also more pronounced 
compared to [18F]-FDG. However, the detailed uptake mechanism of FLT in various tumors 
will be determined. These findings further support our hypothesis that antiproliferative effects 
of drug treatment can be detected early by [18F]-FLT before changes in tumor size become 
visible. A recent study from Leyton et al. also reported a rapid decrease of tumoral [18F]-
FLT-uptake in RIF-1 sarcoma bearing mice as early as 24h after treatment with cisplatin 
(154). In esophageal carcinoma cells, Dittmann showed a rapid decrease of [18F]-FLT-
uptake 24h after therapy with cisplatin (102). A reduction of tumoral [18F]-FLT-uptake related 
to radiotherapy and androgen ablation therapy was demonstrated recently in animal models 
of prostate cancer (155). Using an epidermoid carcinoma xenotransplants model, Waldher et 
al. demonstrated that [18F]-FLT also reflects response to cytostatic therapies such as kinase 
inhibitors (156). 
Up to date, only a few groups studied the potential use of FLT-PET for imaging lymphoma 
and monitoring response to treatment. Our pilot studies suggest that FLT-PET is sensitive 
and specific for detection of lymphoma manifestation sites. It has been demonstrated that a 
linear correlation exists for retention of FLT and proliferation fraction of lymphoma (101, 140). 
Of note, we found a significant increase of apoptotic cells in lymphomas treated with RAD001 
in vivo, but not in vitro. This gives rise to the hypothesis that not only targets within the tumor 
cell, but also within the microenviroment of the tumor seem to contribute to tumor control. 
Indeed, RAd001 potently inhibits growth of stromal and endothelial cells in vitro and reduces 
tumor vascularization in vivo (157).  
Most solid tumors, regardless of their type and origin, cannot grow beyond a certain size (∼1 
mm3) until they establish a blood supply by inducing the formation of new vessels sprouting 
from existing host capillaries, a process known as angiogenesis (158). Accumulating 
evidence suggests mTOR to be a critical component of this process (159), because it is part 
of the phosphatidylinositol 3-kinase/Akt/mTOR signaling pathway, which is also implicated in 
tumor angiogenesis (160). Although the importance of mTOR signaling in the deregulated 
cell growth characteristics of human tumor cells is now widely accepted (117, 161), this 
pathway is also emerging as a key regulator of hypoxia and growth factor-mediated 
expression of tumor hypoxia-inducible factor-1α (HIF-1α) and HIF-1α-responsive genes, such 
as vascular endothelial growth factor (VEGF), as well as endothelial cell function and other 
stromal cells, thereby regulating tumor vascularization (162-164). Furthermore, mTOR is 
considered to be very well conserved and ubiquitously expressed including also in 
endothelial cells (165). RAD001 has been shown previously to have antiangiogenic effects 
including inhibition of human umbilical vein endothelial cell (HUVEC) growth in vitro, 
reductions in expression of HIF-1 and VEGF in cultured tumor cells (166-168), and 
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reductions in blood vessel density (BVD) in several different experimental tumor models (167, 
168). Similar observations are reported for rapamycin (169, 170) and the rapamycin prodrug 
temsirolimus (171, 172). Lane et al. expand on this information by comparing the 
antiangiogenic and antivascular effects caused by mTOR pathway inhibition by RAD001 with 
those of the pan-VEGF receptor (VEGFR) inhibitor vatalanib (PTK/ZK).  They could show 
that RAD001 has significant antitumor activity in mouse tumor models irrespective of in vitro 
sensitivity of the tumor cell lines used or apparently inadequate drug exposure in tumor 
tissue for antiproliferative activity in the insensitive models. Moreover, in both scenarios a 
marked reduction in tumor vascularization and plasma VEGF production is observed. 
Comparisons of the effects of RAD001 on angiogenic processes both in vitro and in vivo with 
those of PTK/ZK indicate overlapping effects on some aspects of endothelial cell biology and 
angiogenic processes, confirming an integral role of the mTOR pathway in VEGFR-induced 
proliferative pathways (173). 
However, PET monitoring of anti-angiogenic effects of RAD001 failed both with FDG- and 
FLT-PET in several tumor entities (174, 175). We have shown that the mTOR inhibitor 
everolimus can rapidly decrease FDG and FLT-uptake in solid tumors that had previously 
been characterized in vitro as sensitive tumors such as SUDHL-1 and Karpas299 tumor. 
Furthermore, Honer et al. have shown that everolimus did not decrease tracer uptake in 
tumors characterized as insensitive in vitro such as HCT116 and KB31. Similar observations 
have been reported for rapamycin on human tumor xenografts where decreases in FDG and 
FLT were linked to changes in hexokinase and thymidine kinase 1 expression (176). 
However, in that report, rapamycin had no effect on the growth of the insensitive tumors in 
vivo even after 2 weeks of daily treatment. Additionally, tumors characterized as insensitive 
in vitro can have significantly reduced growth in vivo in response to everolimus (median T /C 
= 0.43-0.48), an effect not much weaker than in the two sensitive tumor models (median T /C 
= 0.25- 0.27). Such antitumor effects are typical of everolimus monotherapy, which tends to 
reduce tumor growth rather than cause regression (177). These observations on antitumor 
efficacy, coupled with the demonstration that everolimus potently inhibits growth of 
endothelial and stromal cells in vitro, reduces VEGF release from tumor cells, and reduces 
tumor vascularization in vivo (173). This suggests that inhibition of growth of HCT116 and 
KB31 tumors probably includes a substantial antiangiogenic/vascular action. Surprisingly, 
however, the growth inhibitory effect on HCT116 or KB31 in vivo could not be detected by 
changes in uptake of FDG and FLT, suggesting that, for some reason, these PET tracers 
cannot detect an antiangiogenic MoA. This is an important observation because the clinical 
effects of everolimus monotherapy are also characterized by stable disease rather than by 
partial or complete response, that is, tumor growth inhibition rather than regression (178).  
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The Honer group also compare the effect of other compounds that have antiangiogenic or 
cytotoxic action mechanisms on FDG-uptake using an orthotopic mammary model: BN472. 
The BN472 model has been previously characterized as well vascularized, and both 
cytotoxic and antiangiogenic compounds can inhibit its growth (179, 180). Unfortunately, this 
model is not derived from a cell line, and thus, the in vitro sensitivity of everolimus could not 
be assessed, although experiments in vivo showed weak inhibition after 2 weeks of 
treatment suggesting an everolimus-insensitive tumor cell (180). In the BN472 model, the 
microtubule stabilizer patupilone decreased FDG-uptake at both early (day 2) and late time 
points (day 6) while causing tumor stasis. In contrast, NVP-AAL881, a compound that inhibits 
both RAF and the VEGF-R2 (KDR), failed to affect FDG-uptake in the BN472 tumors despite 
causing tumor regression. The pan-VEGF-R inhibitor, PTK/ZK, also failed to reduce FDG-
uptake significantly despite inhibiting the growth of these tumors. Although these results are 
puzzling. The Honer and co-works consider, that there are several possible explanations that 
may contribute to this phenomenon. Those include a) increases in TBF (tumor blood flow) 
and permeability affecting FDG and nutrient delivery, b) a stress response by the tumor cell 
aiming to avoid apoptosis by increasing transport of various nutrients including glucose and 
thymidine, b) decreases in plasma glucose causing a relative increase in the levels of FDG, d) 
induction of hypoxia leading to stimulation of glycolysis through HIF-1, and e) increases in 
the number of glycolytic macrophages that infiltrate the tumor (101, 181-183). Where the 
mechanism for FDG-uptake has been studied, investigations demonstrate that the rate-
limiting step is at FDG phosphorylation by hexokinase rather than FDG transport by glucose 
transporters such as Glut-1 (176, 184, 185). This suggests that changes in TBF are unlikely 
to affect FDG-uptake except perhaps under conditions where TBF is very low, for example, 
in human tumor xenografts (186). However, everolimus has been shown to decrease TBF 
(54, 187), and in the B16/BL6 model described there, they could find no effect at all on the 
parameter BFI (blood flow index), which is equivalent to TBF. Consequently, Honer et al. 
reason that although they did not measure TBF in the xenograft models, it is unlikely that an 
everolimus induced increase in TBF in the insensitive models, for example, through 
normalization (188), can explain the effects observed there. Furthermore, despite a low FDG 
SUV, the fact that Glut-1 levels were very high in the H596 xenograft (and were unaffected 
by everolimus treatment) is also suggestive that nutrient supply is not rate-limiting for FDG-
uptake. There was no evidence that everolimus caused apoptosis in the mouse models, and 
thus, a stress response of increased glucose or thymidine-uptake (thus veiling a decrease in 
FDG- or FLT-uptake) is also unlikely to explain the effects they observed. Furthermore, 
everolimus tends to slightly increase plasma glucose levels (178), which might cause a 
decrease in FDG-uptake in tumor. The influence of plasma glucose has been reported to be 
the order of 10-fold increase in plasma glucose (189, 190). Thus, small changes in plasma 
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glucose are unlikely to affect their observations on FDG-uptake. Hypoxia can be positively 
correlated with glycolysis, but this is not always the case (183), and they did not observe it in 
the BN472 model where there was also no effect of the antiangiogenic PTK/ZK on hypoxia, 
which might have veiled a decrease in FDG-uptake. Finally, an influx of glycolytic 
macrophages after cell kill could also veil a decrease in FDG-uptake. But they did not 
measure macrophages in the xenograft experiments, at least in the rat BN472 model. 
Moreover, an increase in tumor macrophage content seemed not to be an explanation for 
NVP-AAL881 because macrophage levels were actually decreased as measured by a 
contrast-enhanced MRI method, and IHC indicated no change compared with vehicle. 
Thus, taken all together, Honer et al. suggest that anti-angiogenic/vascular inhibition of tumor 
growth does not affect tumor uptake of FDG or FLT as measured by PET in vivo. This may 
be considered a surprising observation, and further clinical confirmation of this hypothesis is 
important. A small FDG-PET study of eight patients with NSCLC showed that everolimus 
induced FDG changes ranging from −72%to +34%, but correlations with patient outcome or 
investigations of antiangiogenic effects were not made (191). Another report from phase 1/2 
studies showed that FDG changes in response to rapamycin were unrelated to tumor 
response by RECIST (192). Honer et al. were not aware of any clinical FDG/FLT-PET 
studies with PTK/ZK or NVP-AAL881, and as reported from B. Besse et al. (2006) the data 
for other agents broadly described as antiangiogenic are minimal. The multikinase inhibitor 
sunitinib has been shown to significantly reduce FDG-PET in some, but not all, patients with 
gastrointestinal stromal tumors, and generally, there was a strong correlation between 
progression-free survival and the early FDG-PET response in this indication (193). However, 
this drug has a strong potency against cellular c-KIT and PDGF-R equaling that against 
VEGF-R2 (194, 195), and thus, its activity is not limited to the stromal compartment of the 
solid tumor. Interestingly, the eponymous antiangiogenic agent bevacizumab when tested for 
clinical activity against tumor blood volume, flow, permeability, interstitial fluid pressure and 
FDG-uptake in a six patients, induced rapid changes in all but FDG-uptake, which only 
changed, if at all, after 3 months of treatment (196). 
Our study have shown that the allosteric mTOR inhibitor everolimus can significantly 
decrease FDG- and FLT-uptake by tumors in mice that are inherently sensitive to the drug. 
However, in less sensitive models where anti-angiogenic/vascular mechanisms probably 
predominate, no effect on these tracers could be detected. In a ratmodel, antiangiogenics 
also failed to affect FDG-uptake (175). These data suggest that FDG-/FLT-PET may provide 
false-negatives for anti-angiogenic/vascular inhibition and, consequently, may not be suitable 
as early response markers for everolimus, other rapalogs, or pure antiangiogenic agents 
(175). 
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These observations as well as the fact, that inhibition of cell proliferation can be a transient 
phenomenon in the setting of intermittent drug administration (143, 144) underline the 
importance of careful consideration of pharmacodynamics in designing imaging protocols for 
response assessment. 
Here we present a translational study including molecular, cellular, as well as animal in vivo 
analyses to validate the predictive value of PET for early assessment of response to targeted 
treatment. Our data provide strong evidence that FLT-, but not FDG-uptake represents a 
reliable, non-invasive surrogate marker to distinguish between sensitive and resistant 
lymphoma early after treatment initiation. These findings will thus facilitate rapid preclinical 
and clinical evaluation of novel inhibitors targeting this pathway as well as drug combinations 
including chemotherapeutic agents. 
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